header logo image


Page 207«..1020..206207208209..220230..»

University of Pittsburgh School of Medicine Launches Neurological Imaging and Therapeutics Center – UPJ Athletics

February 17th, 2021 1:54 am

The University of Pittsburgh School of Medicine today announced the launch of the Alba Tull Center for Neuro Imaging and Therapeutics. The center will be dedicated to designing and expanding imaging technologies for patient care to produce a new, sophisticated understanding of the brain at the molecular level with the goal of developing anti-aging therapeutics.

The Alba Tull Center for Neuro Imaging and Therapeutics is the result of a $1 million grant from the Tull Family Foundation, longtime supporters of the University of Pittsburgh Medical Center. Among the centers other priorities will be training physician-scientists in the imaging technologies uses and finding innovative methods to apply augmented reality (AR) to help guide surgeons hands.

About the foundationThe Tull Family Foundation (TFF) was founded by Thomas and Alba Tull to support organizations that are devoted to transforming the lives of the people in underserved and underfunded communities. A private foundation, TFF funds the advancement of innovative ideas in education, medical and scientific research, and conservation. In 2019, the foundation made a $1.5 million grant to the Children's Hospital of Pittsburgh Foundation to support pediatric research and art therapy programs.

This gift enables a first-of-its-kind center for multidisciplinary collaboration to advance the fields of neuroscience, therapeutics and imaging, said Dr. Anantha Shekhar, senior vice chancellor for the health sciences and John and Gertrude Petersen Dean of the School of Medicine at the University of Pittsburgh. This support from the Tull Family Foundation will expand and enhance the Universitys already robust research in this field.

I am excited about the opportunity to advance our work in neuro AR, chemistry and personalized medicine, keeping us at the forefront of patient care and research breakthroughs, said Robert Friedlander, MD, Walter E. Dandy Professor and chairman of the University of Pittsburgh Department of Neurological Surgery and co-director of the UPMC Neurological Institute. Dr. Friedlander also highlighted the key role Joseph Maroon, MD, clinical professor of neurological surgery at the University of Pittsburgh Medical Center, played in securing this important gift.The Alba Tull Center will encourage researchers to collaborate on leading cross-disciplinary projects exploring new frontiers in imaging technology and its applications. Work will include the development of a single, non-invasive scan, known as radiomics, that integrates multiple patient records to predict responses to therapies in order to help determine the best course of treatment. It will also enhance high-definition imaging of fiber connections in the brain to better fight tumors without damaging other tissue.

Alba Tull added, The past year, more than ever, has underscored the power medicine has to change the world and the future. Supporting leading medical care and research is one of our priorities and this new center will enable scientific innovations from allowing physicians to examine a patients brain without making an incision to guiding surgeons hands in real-time when invasive treatment is the only option. We are proud to be able to support the University of Pittsburgh School of Medicine and look forward to continuing to work together.

The University of Pittsburgh Department of Neurosurgery is the largest neurosurgical academic provider in the United States, with UPMC clinicians performing more than 12,000 procedures annually, and ranked among the top five neurosurgical residency programs in the country in terms of academic publishing output of faculty. The department is guided by three core goals: to provide outstanding care to patients with neurological disease; to equip neurosurgeons of the future with state-of-the-art techniques and analytical skills to lead the field of neurosurgery; and to foster research designed to enhance the treatment of diverse diseases affecting the nervous system.

See the article here:
University of Pittsburgh School of Medicine Launches Neurological Imaging and Therapeutics Center - UPJ Athletics

Read More...

Tenet, Providence, other health giants band together to form new health data startup – FierceHealthcare

February 17th, 2021 1:54 am

Some of the biggest names in healthcare including Tenet Health, Providence and CommonSpirit Health have launched a new startup to pool and analyze patient data for research and drug development.

Capitalizing on health systems' troves of patient data, 14 health systems are backing the new company, called Truveta. Among the backers are AdventHealth, Advocate Aurora Health, Baptist Health of Northeast Florida, Bon Secours Mercy Health, Hawaii Pacific Health,Henry Ford Health System,Memorial Hermann Health System,Northwell Health, Novant Health, Sentara Healthcare and Trinity Health.

The Seattle-based startup will pull together and sell normalized andde-identifieddata from the group of providers with a keeneye onprotecting patient privacy and security, the companies said in a press release.

Disruption, Acceleration & Innovation: Pharmacists on the Frontline

This year, pharmacists will play a critical role in the United States COVID-19 immunization efforts. Although this is welcomed news, this new duty and other coronavirus responsibilities are exacerbating pharmacist burnout. In this panel, experts will explore how pharmacists can leverage technology to automate administrative tasks and satisfy patient needs.

The new data platform, using the power of artificial intelligenceand machine learning, will helpdeliver "personalized medicine, advance health equity, and empower the health community with insights on how to best treat patients," the press release said.

The 14 health systems representtens of millions of patients and operate thousands of care facilities across 40 states.

RELATED:Mayo Clinic taps Google Cloud as strategic partner to accelerate innovation in AI, analytics and digital tools

Truveta will be jointly ownedby the hospital operators and willbe board-advised with a strong focus on ethics and health equity, data integrity and clinical outcomes.

Former Microsoft executive Terry Myerson will lead the new startup.

Myerson told The Wall Street Journal that the company is still developing its pricing plans. Potentially, fees will vary depending on the type of entity seeking access, the WSJ reported.

The COVID-19 pandemic has shown us how much the world needs to learn faster, so we can better serve our communities, Myerson said in a statement.Our vision is to save lives with data. We want to help researchers find cures faster, empower every clinician to be an expert, and help families make the most informed decisions on their care. We believe the Truveta platform can help improve health equity and advance personalized medicine. We are honored to be partnering with innovative and world-class health providers in this pursuit.

For years we have seen the opportunity for diverse health providers to come together with a shared sense of purpose and use our collective data for the common good of humanity. With Truveta, we created a unique model that is led by the health providers yet supported by one of the most talented technical teams to focus on health, said Rod Hochman, M.D, president and CEO of Providence, in a statement.

Hochman said the hospital systems will focus on research questions around health equity as well as improving medical treatment, the WSJ reported.

The COVID-19 pandemic illustrates how quickly healthcare must move to effectively serve patients, according to the companies. The healthcare community has made remarkable progress, from diagnosis to vaccine distribution in less than a year.

Truvetas innovative health provider partners agree COVID-19 must be a catalyst for even more rapid progress,the companies said in the press release.

Truveta aims todrive innovation in patient care and the development of new therapies through the creation of adata platform researchers can use to analyzebillions of clinical data points with a single search.

RELATED:Google, Ascension defend their health 'data transformation' partnership

The Truveta platform will structure and normalize a wide range of data across structured and unstructured data types to unlock the power of de-identified data across all diagnoses, geographies and demographics. Using advanced AI and machine learning, Truveta will deliver continuous learning to physicians, researchers, biopharma and more with aggregate analysis of conditions, therapies and prognoses, according to the press release.

Health system leaders involved in the effort said protecting patient data privacy would be a key priority forTruveta.

We know health data is unlike other data. It is the very definition of personal, Myerson said. While we embark on our pursuit to generate knowledge and insights to improve patientcare around the world, we must do so with the utmost caution to protect the privacy of patients.

The initiativeis an important step in unlocking the hidden insights from data sitting in silos in large health systems, saidPaddy Padmanabhan, founder and CEO of Damo Consulting, a growth strategy and digital transformation advisory firm.Healthcare has been hobbled by the inability to harness available data to improve healthcare outcomes, enhance patient experiences and reduce health inequities," he said.Truveta's success will depend on execution, he added.

Where will the data be hosted? How will Truveta build the advanced analytics and AI capabilities required to turn the vision to reality?" he said. Truveta is a welcome new approach to industry-level collaboration for turning data into insights. However, the fact is that it is a collaborative effort among health systems and the data sets therefore provide only a partial view of patient histories for driving innovations in care management and developing new therapies."

Over the longer term, the industry will need to achieve active collaboration across health plans and life sciences companies as well tounleash innovation in new therapies, drive research and improve healthcare outcomes,Padmanabhan said.

See more here:
Tenet, Providence, other health giants band together to form new health data startup - FierceHealthcare

Read More...

National health database opens to University researchers – University of Miami

February 17th, 2021 1:54 am

Already containing health records, surveys, and measurements from more than 200,000 people from all walks of life, the All of Us Research Programs Researcher Workbench is a treasure trove waiting to be mined.

An immigrant from Peru, Dr. Ral Montaez-Valverde was surprised to encounter perplexing research showing that Latinos in the United States are at lower risk of heart disease than their white counterpartsdespite a generally lower socioeconomic status and access to health care.

It prompted me to think about why Hispanics could have better outcomes, given all the challenges, said Montaez-Valverde. I was very curious about this question.

So curious that, despite his intense schedule as a second-year internal medicine resident at Jackson Memorial Hospital, Montaez-Valverde jumped at the chance to use the All of Us Research Programs Researcher Workbench to investigate the long-debated validity of whats known as the Latino Epidemiological Paradox. Now open to investigators from all disciplines and career stages across the University of Miami, the Researcher Workbench contains the de-identified electronic health records of more than 200,000 people across the United Statesincluding 10,000 from Greater Miamiwho have enrolled in the most inclusive study ever undertaken by the National Institutes of Health.

Launched in 2018, the 10-year, $2 billion-plus All of Us Research Program (AoURP) is building one of the worlds largest and most diverse health datasets by collecting lifestyle, health, and genetic information from 1 million people of all races, ethnicities, backgrounds, and gender identities living in the U.S. The ultimate goal is to advance personalized medicine by helping researchers and physicians like Montaez-Valverde understand why different people are more vulnerable to different diseases and conditions and tailor prevention, treatment, and care approaches specifically for them.

But neither the AoURP nor the Universitys Miller School of Medicine, which is leading the AoURPs effort to recruit some 80,000 of the 1 million participants from Florida and Georgia, are waiting for the enrollment process to conclude before making the data available to researchers. The University has signed a data-use agreement with the NIH allowing any faculty members, research assistants, students, residents, or other trainees with an NIH eRA Commons account to begin mining the treasure trove, which will grow in both value and volume as more people discover its riches.

The Researcher Workbench is a major milestone in fulfilling the promise of the All of Us program, but for now it may be one of the best kept secrets in biomedical research, said Stephan Zchner, professor and chair of the Dr. John T. Macdonald Foundation Department of Human Genetics and the lead principal investigator for the AoURPs Southeast Enrollment Center (SEEC), which also includes the University of Florida, Emory University, and Morehouse School of Medicine.

At the end of the day, continued Zchner, who also co-directs the John P. Hussman Institute for Human Genomics, we want to work with data to create new knowledge and insights into medicine, and the workbench is a major tool for that. Whats exciting is that it opens biomedical data access to many qualified investigators, including people in the social sciences, basic sciences, sports, even the arts. The possibilities are endless, and there will be a lot more of them as the data get richer and larger over time.

For the time being, the cloud-based research platform, which requires proficiency with the R or Python programming languages, does not include the genetic information that most interests researchers like Zchner. But as he noted, the AoURP is currently sequencing the genomes of the first 100,000 participants and plans to do the same for all 1 million participantsall of which eventually will make its way into the database and the hands of those who shared their DNA.

Yet even in its infancy, the workbench already contains four types of data. In addition to the electronic health records of roughly 203,000 people, the database includes survey data from more than 315,000 people who answered questions about their medical history, lifestyle, access to care and, more recently, experiences with COVID-19, including the pandemics impact on their mental and financial health. It also contains physical measurementsincluding blood pressure, heart rate, and body mass indexfrom more than 260,000 people, and data collected by the Fitbit wearable devices of more than 8,000 people.

But for Dr. Olveen Carrasquillo, an expert in health disparities who serves as the SEECs participant engagement lead, the most exciting aspect of the AoURP is its success in recruiting minorities who have long been overlooked by medical research. According to the AoURP, about half of the participants whose data is in the Researcher Workbench are people of color.

One of my biggest concerns was that this project would be like everything else, and minorities would be left out, but weve seen really robust and good efforts at assuring they are included, said Carrasquillo, professor of public health sciences, chief of the Division of General Internal Medicine, and a co-principal investigator for the AoURP. And by minorities, I mean that in the full sense, not just race and ethnicity, but by income, education, gender identity. So, with lots of data on minorities, this humongous data source will be a very powerful tool for people who want to reduce health disparities and improve health equity.

To get an idea of its power, Carrasquillo enlisted Montaez-Valverde, the resident he happened to meet on the Metrorail after leaving Jackson Memorial one night, to become one of the Universitys first workbench users. At the time, Montaez-Valverde, who plans to specialize in cardiology, wasnt familiar with the AoURP, or the Latino paradox. But he shared Carrasquillos skepticism that, given their higher rates of diabetes and uncontrolled blood pressure, Latinos would have better cardiovascular health than their white counterparts, as other studies have shown.

Montaez-Valverde was amazed to learn he would have the electronic records of more than 200,000 people to analyze, a powerful tool that helped him conclude that Latinos in the AoURP dataset actually have a higher, not lower, or similar prevalence of cardiovascular disease, than whites. He was just invited to present those findings at theAmerican College of Cardiologys 70th annual scientific session in May.

What we saw clearly does not support the Latino paradox, Carrasquillo said. But thats only in this database, so for now were just throwing more fire on a debate thats been raging for 25 years.

But not subject to much debate will be the growing value of using the AoURP Research Workbench for research and discovery. As the data grow, the research is going to be a lot more powerful, meaningful, and useful, he said.

To learn more about the workbench, visit the All of Us Research Hub or listen to an overview by Drs. Zchner and Carrasquillo presented by the Clinical and Translational Science Institute. For more information about or to enroll in the study, visit the All of Us Research Program.

Go here to read the rest:
National health database opens to University researchers - University of Miami

Read More...

Ben-Gurion University Researchers Develop Novel Method for Personalizing Dose of Schizophrenia Drug Clozapine – BioSpace

February 17th, 2021 1:54 am

Method utilizes electronic sensor that instantly and accurately detects concentrations of the antipsychotic drug, clozapine, in the blood via a finger prick, allowing maximal therapeutic benefit while minimizing side effects

BEER-SHEVA, Israel, Feb. 16, 2021 /PRNewswire/ -- Researchers at Ben-Gurion University of the Negev (BGU) have developed a novel method for instantly and accurately monitoring blood levels of the antipsychotic drug, clozapine, using a blood drop from a finger prick. The method, developed by Dr. Hadar Ben-Yoav, Department of Biomedical Engineering and Ilse Katz Institute for Nanoscale Science and Technology, BGU, is based on an electrochemical microsensor which enables, for the first time, clozapine detection in one drop of finger-pricked whole blood samples of schizophrenia patients without using any pretreatment steps.

Clozapine is considered the most effective antipsychotic medication for schizophrenia and the only antipsychotic currently approved for treatment-resistant schizophrenia but is also associated with harsh side effect. Both its efficacy and its side effects are strongly correlated with blood concentration levels, which can differ up to 20-fold between individuals prescribed identical doses, and can be greatly affected by age, gender, drug interactions and other parameters.

Despite the importance of monitoring clozapine blood levels, its current monitoring scheme is burdensome and involves frequent invasive blood draws, leading to sub-optimal treatment efficacy due to the poor ability to titrate its dose for maximal therapeutic benefit while minimizing side effects. As a result, clozapine is still one of the most underutilized evidence-based treatments in the field of mental health.

Dr. Ben-Yoav's team has invented a miniaturized microelectrode sensor that is able to accurately and immediately detect clozapine levels in a microliter-sample of whole blood such as obtained by a simple finger prick. A recent study carried out in collaboration with Prof. Deanna L. Kelly, Maryland Psychiatric Research Center (MPRC), University of Maryland, School of Medicine, showed good correlation between clozapine blood concentrations measured by the device compared to standard laboratory blood tests in schizophrenia patients[i].

Dr. Ben-Yoav, said, "We were excited to see the promising initial results of our novel device, that can supply people with schizophrenia and their caretakers with instantaneous, accurate results of their blood clozapine levels. Clozapine plasma levels are helpful in improving response rates and minimizing unnecessary side effects. Our device can be the basis of rapid, accurate point-of-care monitoring of patients that will enable personalized medicine through close monitoring and adjustment of the dose of this important drug."

"We hope that this innovative invention will help increase patient compliance and facilitate the use of clozapine for people living with schizophrenia," said Josh Peleg, CEO of BGN Technologies. "The medical research field is investing considerable efforts in simplifying and miniaturizing various blood tests, enabling patients to receive medical results immediately and at home, and the device being developed by the team of Dr. Ben-Yoav is an important contribution to this trend. Importantly, the technology underlying this novel clozapine sensor can be used as a platform for the detection of additional substances. After filing for patent protection, BGN Technologies is currently seeking a strategic partner for further developing and commercializing this device."

The novel sensor can be used as a platform for detecting other redox (reducing-oxidizing) chemicals in small quantities of untreated, whole blood samples. Redox molecules are involved in multiple significant chemical reactions, such as synthesis of various substances, biochemical processes in living organisms, diagnostics and medical procedures. Redox agents can be monitored by specific electrodes, but currently available methods of detection require pretreatment of the blood sample in order to separate the desired molecules from other, interfering substances. The sensor developed by Dr. Ben-Yoav's team can detect minute quantities of various redox molecules in untreated blood samples, thus paving the way for developing miniaturized, point-of-care devices that will be able to monitor various targets.

In August 2020, Dr. Ben-Yoav was one of the recipients of the Brain & Behavior Research Foundation's 2020 Klerman and Freedman Prizes, recognizing exceptional clinical and basic research in mental illness. The prizes are awarded annually to honor outstanding scientists working to advance the prevention, diagnosis and treatment of psychiatric illness. Dr. Ben-Yoav received the prize for his development of "novel biosensors to detect unique diagnostic electrical fingerprints from blood samples of schizophrenia patients that can provide crucial information about their treatment management."

References:

[i] Shukla et al. (2020) An integrated electrochemical microsystem for real-time treatment monitoring of clozapine in microliter volume samples from schizophrenia patients. Electrochemistry Communications 120 (2020) 106850; https://doi.org/10.1016/j.elecom.2020.106850

About BGN Technologies

BGN Technologies is the technology transfer company of Ben-Gurion University, the third largest university in Israel. BGN Technologies brings technological innovations from the lab to the market and fosters research collaborations and entrepreneurship among researchers and students. To date, BGN Technologies has established over 100 startup companies in the fields of biotech, hi-tech, and cleantech, and has initiated leading technology hubs, incubators, and accelerators. Over the past decade, BGN Technologies has focused on creating long-term partnerships with multinational corporations such as Deutsche Telekom, Dell-EMC, PayPal, and Lockheed Martin, securing value and growth for Ben-Gurion University as well as the Negev region. For more information, visit the BGN Technologies website.

Media Contact: Tsipi HaitovskyGlobal Media LiaisonBGN TechnologiesTel: +972-52-598-9892E-mail: tsipihai5@gmail.com

View original content:http://www.prnewswire.com/news-releases/ben-gurion-university-researchers-develop-novel-method-for-personalizing-dose-of-schizophrenia-drug-clozapine-301228713.html

SOURCE BGN Technologies

Read the rest here:
Ben-Gurion University Researchers Develop Novel Method for Personalizing Dose of Schizophrenia Drug Clozapine - BioSpace

Read More...

[Full text] Familial Hypercholesterolemia: A Narrative Review on Diagnosis and Man | VHRM – Dove Medical Press

February 17th, 2021 1:54 am

Introduction

Low-density lipoprotein (LDL) cholesterol has been identified as the causative factor for atherosclerotic cardiovascular disease (ASCVD) based on a variety of evidence obtained from epidemiology,1 human pathology,2 human genetics,3 and clinical trials.47 Familial hypercholesterolemia (FH), an inherited hyper-LDL cholesterolemia, has often been associated with tendon and cutaneous xanthomas and premature ASCVD.8 This disorder has been regarded as a Mendelian autosomal dominant disease caused by rare genetic mutation(s) in the LDL receptor or its associated genes. Theoretically, this disease can be diagnosed at the early stages of life, even as early as pregnancy. Currently, two major methods have been proposed for the screening of FH worldwide.9 The first approach involves cascade screening where a diagnosis of FH in new cases, typically younger relatives, is triggered by the diagnosis of the index cases. The second approach involves universal screening where LDL cholesterol measurements are conducted universally at a certain age, after which detailed assessments, including genetic analyses, are subsequently performed to confirm their diagnoses. However, diagnosing FH in children and adolescents is often quite difficult given that physical xanthomas and family histories are usually obscure and/or difficult to obtain among such young patients.

Apart from the difficulties in diagnosing FH among children and adolescents, debates regarding when, how, and who to treat at this early stage of life have remained ongoing. In this regard, recent advancements in human genetics have revealed that personalized medicine can also be applicable to FH, where patients with deleterious genetic mutations and/or signs of premature atherosclerosis development should be treated earlier and more aggressively.10 On the other hand, children and adolescents with FH who had started early treatment exhibited excellent prognosis even under mild treatment,11 suggesting the importance of earlier treatment in the management of FH.

The current review outlines the current status of clinical and genetic diagnosis of FH in children and adolescents while also providing useful management strategies for FH in children and adolescents based on currently available clinical evidence.

FH is characterized by the clinical triad of primary hyper-LDL cholesterolemia, tendon xanthomas, and premature ASCVD.12 The first documentation of FH dates back as far as 1873,13 during which it had been described as xanthomatous disease. By the 1930s, FH had started to be considered as an inherited disease,14 with Prof. Brown and Goldstein later discovering genetic abnormalities in the LDL receptor as the principal cause of this condition by the 1970s.15 Subsequently, other genes, including apolipoprotein B (APOB)16 and proprotein convertase subtilisin/kexin type 9 (PCSK9)17 genes, have also been identified to cause this disease. Since its initial documentation, FH has long been described to have a prevalence of 1 in 500 individuals among the general population. In 2011, our group found that FH had a prevalence of 1 in 208 based on genetic epidemiology of homozygous FH in the Hokuriku district of Japan.18 Following our report, similar estimates have been obtained in the United States and Europe.19,20 Currently, FH is considered to have a prevalence of 1 in ~300 individuals among the general population.21 By such estimates, only one monogenic mutation causes the critical phenotype. Monogenic FH is considered the standard form of FH, wherein the mutation status of affected genes is associated with increased likelihood of developing ASCVD, independent of LDL cholesterol values.22 This disease appears to account for at least a portion of patients with ASCVD (estimated to be ~1 in 31 individuals), especially those with premature ASCVD (estimated to be ~1 in 15 individuals). No other single disorder can be responsible for such proportions of ASCVD, which has been identified as the leading cause of mortality worldwide.23 Moreover, timely diagnosis and treatment of children and adolescents with FH have been shown to promote a favorable prognosis.11 Accordingly, children and adolescents with require better awareness and more attempts at diagnosing FH compared to adults.

As stated previously, timely diagnosis and treatment has been shown to prevent ASCVD events in patients with FH. As such, identifying patients with FH at a younger age is of particular importance given that this leads to prompt treatment initiation and prevention of premature ASCVD. However, diagnosing FH in younger individuals is somewhat difficult considering that they typically do not exhibit increased Achilles tendon thickness, which has been used as one of the major diagnostic criteria for adult FH worldwide. One proposed screening method for FH is universal screening at an age when FH can be effectively identified.24,25 On the other hand, opportunistic screening, utilizing every opportunity to screen patients for FH, is also effective to find FH.2628 For example, measurement of LDL cholesterol is common practice, and we can find patients with FH when LDL cholesterol level is over a threshold irrespective of the primary aim of its measurements. Another effective screening method for FH is cascade screening, which has been recommended by many organizations around the world. Indeed, countries where dedicated cascade screening programs have been implemented have identified a notably higher number of patients with FHs. For instance, the Netherlands and Norway have diagnosed 71% and 43% of FH cases, respectively.29 In addition, we had demonstrated that cascade screening is significantly associated with better prognoses among patients with FH30 One of the major factors contributing to our results is the notion that an earlier diagnosis promotes better outcomes, which is especially true for patients with FH. As such, although numerous studies have shown the efficacy of LDL-lowering therapies among patients with FH, the magnitude of the benefits obtained from such therapies appear to vary according to the timing of therapy commencement, with far greater benefits having been observed among children than among adults in secondary prevention settings.11,30,31 Accordingly, we firmly believe that earlier diagnosis either via cascade or universal screening and timely LDL-lowering therapies could be beneficial for patients with FH. Alternative way of screening for FH is reverse cascade screening where the index case is a child, and then parents are diagnosed as FH.32,33 It is usually associated with universal screening. However, studying the parents first has a high diagnostic yield.34

Several different types of clinical diagnostic criteria have been established for FH globally, including the Dutch Lipid Clinical Network (DLCN),35 Make Early Diagnosis to Prevent Early Deaths (MEDPED) diagnostic criteria,36 Japan Atherosclerosis Society (JAS) FH diagnostic criteria,37 and Simon Broome diagnostic criteria for FH.35 Each of the aforementioned diagnostic criteria for pediatric FH has specific cutoffs for LDL cholesterol (Boxes 1 and 2; Tables 1 and 2) given the considerable variability in its levels within this group, especially among adolescents.38 Moreover, children and adolescents with FH barely exhibit physical xanthomas, which is one of the major clinical diagnostic criteria for adults. Nonetheless, care should be exercised when using lower LDL cholesterol thresholds for screening young patients with FH, with family history being much more important in pediatric than in adult cases. In this regard, clinical diagnostic criteria for pediatric FH by JAS appears to be quite useful. Because it is quite simple to use (there are only 2 elements), and it really put weight on their family history (of parents). In order to diagnose them as FH, (reverse) cascade screening for FH will be conducted, and then at least 2, or perhaps even more patients with FH can be identified.

Box 1 Diagnosis of Familial Hypercholesterolemia in Children and Adolescents (EAS)

Box 2 Pediatric Familial Hypercholesterolemia Diagnostic Criteria (JAS)

Table 1 Diagnosis of Familial Hypercholesterolemia (MEDPED)

Table 2 Simon Broome Diagnostic Criteria for FH

To establish a diagnosis of FH in children and adolescents, genetic testing may be quite useful, although ethical aspects should be carefully considered.39 However, we also need to be careful for what is FH. A few years ago, an useful classification has been proposed regarding the classification of FH. According to this, FH can be classified into heterozygous FH (caused by a deleterious mutation in FH-gene), homozygous FH (caused by double deleterious mutations in FH-gene), polygenic FH (caused by LDL-associated common genetic variations), and polygenic FH plus hypertriglyceridemia (caused by LDL-, and TG-associated common genetic variations).40 In terms of genetic diagnosis, it is still quite difficult to diagnose polygenic state of FH. Accordingly, genetic diagnosis of FH is usually referring to genetic testing for rare genetic variations of FH-genes. In addition, it is also important to think differently between heterozygous FH and homozygous FH irrespective of ages. As stated above, the prevalence of heterozygous FH is 1 in ~300 among general population, which is a common disorder, and difficult to diagnose them as FH in children adolescents because of reasons stated previously. On the other hand, homozygous FH is a rare condition, the prevalence of which is estimated to 1 in 160,000 among general population. However, it is of note that state of homozygous FH is an emergent condition, where cardiovascular complications are observed in their adolescence.8 There are several special treatments for homozygous FH, including microsomal triglyceride transfer protein (MTTP) inhibitor, LDL apheresis, and liver transplantation.4145 Genetic diagnosis for homozygous FH is very important not just because of their diagnosis, but can be useful for their phenotyping. It has been shown that PCSK9 inhibitor, which is quite useful for heterozygous FH, has minimal effect to reduce LDL cholesterol level among the patients with homozygous FH caused by null-type of mutations of LDLR.46 Other useful points for this matter include assessment of responsiveness to dietary intervention, although dietary interventions typically have minimal influence on LDL cholesterol levels among pediatric patients with FH.47 Moreover, an important differential diagnosis worth considering in pediatric FH includes sitosterolemia,48,49 a disease found to be a phenocopy of homozygous FH. Although patients with sitosterolemia usually exhibit physical xanthomas associated with elevated LDL cholesterol, sitosterolemia is a recessive disorder, with dietary interventions being quite useful for reducing LDL cholesterol levels.50 Sitosterolemia can be distinguished from FH based on the mentioned important clinical manifestations.

FH has been considered one of the major causes of premature ASCVD, with carotid ultrasound being one of the most popular and non-invasive methods for assessing atherosclerosis among pediatric patients with FH. Carotid intima-media thickness (IMT) is often used as a surrogate marker for systemic atherosclerosis among not only the general population but also pediatric patients with FH.51,52 Moreover, coronary and/or aortic calcium scores have been used to assess early subclinical atherosclerosis,53 apart from actual plaque accumulation in the coronary artery.54 Furthermore, arterial stiffness assessed through brachial-ankle pulse wave velocity had been found to be significantly associated with the presence of ASCVD in patients with FH.55 According to accumulated evidence obtained thus far, the development of ASCVD among patients with FH appears to start during adolescence. These findings have motivated us to consider initiating LDL cholesterol-lowering treatments at an earlier stage of life.

Lifestyle interventions should be the fundamental strategy for managing FH in children and adolescents at any age. Statins can be introduced according to guidelines or recommendations. For instance, pitavastatin can be used for Japanese pediatric patients with FH (age 10 years) whose LDL cholesterol levels remain 180 mg/dL under lifestyle interventions, with the optimal target being set at <140 mg/dL, especially among those with diabetes or a family history of premature ASCVD (Figure 1).37 There are many studies showing the efficacy and safety regarding the use of statins for children and adolescents, and a meta-analysis and a systemic review are suggesting that it is true.56,57 Adherence should be closely monitored among those with poor response to statins before increasing the dose. Adolescent girls should be counseled to suspend statin therapy when contemplating pregnancy. Other medications, such as ezetimibe and resin, can be considered when needed. Notably, the European Atherosclerosis Society had proposed a similar strategy in Europe where high-risk pediatric patients with FH aged 810 years are recommended to start statins to reduce LDL cholesterol (Figure 2).10 Moreover, the National Lipid Association expert panel on FH had recommended similar management approaches (Box 3).58 In addition, resin, and ezetimibe are also shown to effectively reduce LDL cholesterol among the pediatric FH patients.59,60 More recently, it has been shown that evolocumab reduced the LDL cholesterol level and other lipid variables among them.61 Notably, all of the mentioned recommendations have acknowledged the need for actively attempting to diagnose/identify FH in children and adolescents and considering lowering LDL cholesterol levels through lifestyle intervention and statins.62

Figure 1 Strategies for the management of pediatric familial hypercholesterolemia (FH) (JAS). Green arrows indicate Yes; blue arrows indicate No. The essential message is that the pediatric patients with FH aged 10 or greater who have low-density lipoprotein cholesterol levels 180 mg/dL under appropriate lifestyle intervention may be treated using statins. Reproduced from Harada-Shiba M, Ohta T, Ohtake A, et al. Joint Working Group by Japan Pediatric Society and Japan Atherosclerosis Society for Making Guidance of Pediatric Familial Hypercholesterolemia.Guidance for Pediatric Familial Hypercholesterolemia 2017.J Atheroscler Thromb. 2018;25(6):539553.37

Figure 2 Strategies for the diagnosis and management of familial hypercholesterolemia (FH) in children and adolescents (EAS). Premature coronary heart disease is defined as a coronary event before age 55 and 60 years in men and women, respectively. Definite FH is defined as genetic confirmation of at least one FH-causing genetic mutation. Close relative is defined as 1st or 2nd degree relatives. Highly probable FH is based on clinical presentation (ie, phenotypic FH): either an elevated low-density lipoprotein cholesterol (LDL-C) level 5 mmol/L in a child after dietary intervention or a LDL-C level 4 mmol/L in a child with a family history of premature coronary heart disease in close relatives and/or high baseline cholesterol in one parent. Cascade screening from an index case with a FH-causing mutation may identify a child with elevated LDL-C levels 3.5 mmol/L. Reproduced with permission from Wiegman A, Gidding SS, Watts GF, et al. European atherosclerosis society consensus panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):24252437.10

On the other hand, there are other strategies, including MTTP inhibitor (lomitapide), APOB inhibitor (mipomersen), LDL apheresis, and liver transplantation for the cases with homozygous FH. Another potential medical therapy is Angiopoietin-like 3 (ANGPTL3) inhibitor, whose efficacy and safety for adult patients with homozygous FH has been shown.63

Box 3 Summary Recommendations from the National Lipid Association Expert Panel on Treatments for Pediatric Familial Hypercholesterolemia

Regardless of its definition, genetic analyses for patients with FH should have clear indications beyond clinical diagnosis. As such, we herein highlight the several advantages of genetic background analysis in FH. First, quite a few patients with hypercholesterolemia have obscure or marginal clinical diagnoses of FH. Moreover, their family history is sometimes quite challenging to obtain. Genetic analyses can definitively identify patients with FH, especially those with traditional monogenic FH. Second, genetic analysis allows us to determine whether patients are heterozygous or homozygous. Several special medical therapies, such as MTTP inhibitors and LDL apheresis, have typically only been used for homozygous FH in many parts of the world. Moreover, homozygous FH is one of the designated intractable diseases where all medical costs can be covered by the Japanese government, thereby increasing the importance of diagnosis. Third, a portion of patients with FH may have been misdiagnosed as such and actually have another diagnosis, such as sitosterolemia. In such cases, ezetimibe instead of statins is recommended. Fourth, the genetic status of patients with FH has been found to be associated with increased risk for ASCVD. Accordingly, determining the genetic status can lead to better risk stratification. Fifth, genetic status determination can lead to better cascade screening and consequently better prognoses. Panel sequencing covering FH genes appears to be the current gold standard for determining the genetic status.64 However, determining the pathogenicity of the identified genetic variations has remained challenging for us.

We currently face an important dilemma regarding the definition of FH. If we adhere to clinical manifestations, such as tendon xanthomas, we believe that it is too late considering that earlier interventions based on earlier diagnosis have already been proposed. We believe that at least two different types of diagnostic criteria can be established. The first criteria, which would aim to diagnose definite FH, can be rather strict and have high diagnostic specificity, whereas the second one, which would aim to diagnose potential FH, can have high diagnostic sensitivity. Nonetheless, a diagnosis of FH needs to be ultimately established and adequately treated as early as possible before pediatric patients grow into adults.

Data science and personalized medicine are two major keywords describing medical innovations in the coming 10 years. In the management of FH, genetic analyses involving genes associated with not only LDL cholesterol itself but also ASCVD will become standard. Moreover, target, timing, and LDL cholesterol-lowering therapies will become quite individualized based on genotype, lifestyle, environmental factors, and belief systems. For the earlier identification of patients with FH, nation-wide mass screening, similar to that currently conducted for several other inherited metabolic diseases, such as newborn screening, phenylketonuria, and homocystinuria, will become standard. Furthermore, family history will be automatically assessed to accumulate a huge dataset over the years, which will help us minimize the risk of overlooking children and adolescents with FH (and other inherited diseases).

Given that FH is an inherited disease, early diagnosis and intervention can lead to excellent prognosis. Cascade and universal screening appear to be practical strategies for the early identification of patients with FH; however, we need to consider that certain clinical approaches can promote better identification of children and adolescents with FH. Clinical practices and genetic analyses will certainly help improve not only diagnostic accuracy but also risk stratification for personalized medicine.

The authors report no conflicts of interest in this work.

1. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971;74(1):112. doi:10.7326/0003-4819-74-1-1

2. Friedman M. Pathogenesis of the spontaneous atherosclerotic plaque. A study on the A/Friedman M: pathogenesis of the spontaneous atherosclerotic plaque. A study on the cholesterol-fed rabbit. Arch Pathol. 1963;76:318329.

3. Tada H, Usui S, Sakata K, Takamura M, Kawashiri MA. Low-density lipoprotein cholesterol level cannot be too low: considerations from clinical trials, human genetics, and biology. J Atheroscler Thromb. 2020;27(6):489498. doi:10.5551/jat.RV17040

4. Baigent C, Blackwell L, Emberson J, Cholesterol Treatment Trialists (CTT) Collaboration, et al.. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:16701681.

5. Cannon CP, Blazing MA, Giugliano RP, IMPROVE-IT Investigators, et al.. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):23872397. doi:10.1056/NEJMoa1410489

6. Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER steering committee and investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):17131722. doi:10.1056/NEJMoa1615664

7. Schwartz GG, Steg PG, Szarek M, ODYSSEY OUTCOMES Committees and Investigators, et al.. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):20972107. doi:10.1056/NEJMoa1801174

8. Mabuchi H. Half a century tales of familial hypercholesterolemia (FH) in Japan. J Atheroscler Thromb. 2017;24(3):189207. doi:10.5551/jat.RV16008

9. Gidding SS, Champagne MA, de Ferranti SD, et al. American heart association atherosclerosis, hypertension, and obesity in young committee of council on cardiovascular disease in young, council on cardiovascular and stroke nursing, council on functional genomics and translational biology, and council on lifestyle and cardiometabolic health. The agenda for familial hypercholesterolemia: a scientific statement from the American heart association. Circulation. 2015;132(22):21672192. doi:10.1161/CIR.0000000000000297

10. Wiegman A, Gidding SS, Watts GF, et al. European atherosclerosis society consensus panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):24252437. doi:10.1093/eurheartj/ehv157

11. Luirink IK, Wiegman A, Kusters DM, et al. 20-Year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med. 2019;381(16):15471556. doi:10.1056/NEJMoa1816454

12. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2001:2863e913.

13. Fagge CH. Xanthomatous disease of the skin. I. general xanthelasma of vitiligoides. Trans Pathol Soc. 1873;24:242250.

14. Thannhauser SJ, Magendantz H. The different clinical groups of xanthomatous diseases: a clinical physiological study of 22 cases. Ann Intern Med. 1938;11(9):1162. doi:10.7326/0003-4819-11-9-1662

15. Brown MS, Goldstein JL. Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3hydroxy-3-methylglutaryl coenzyme A reductase activity. Proc Natl Acad Sci U S A. 1974;71(3):788792. doi:10.1073/pnas.71.3.788

16. Innerarity TL, Weisgraber KH, Arnold KS, et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci U S A. 1987;84(19):69196923. doi:10.1073/pnas.84.19.6919

17. Abifadel M, Varret M, Rabs JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154156. doi:10.1038/ng1161

18. Mabuchi H, Nohara A, Noguchi T, et al. Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan. Atherosclerosis. 2011;214(2):404407. doi:10.1016/j.atherosclerosis.2010.11.005

19. Benn M, Watts GF, Tybjrg-Hansen A, Nordestgaard BG. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen general population study estimated a prevalence of 1 in 217. Eur Heart J. 2016;37(17):13841394. doi:10.1093/eurheartj/ehw028

20. de Ferranti SD, Rodday AM, Mendelson MM, et al. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States national health and nutrition examination surveys (NHANES). Circulation. 2016;133(11):10671072. doi:10.1161/CIRCULATIONAHA.115.018791

21. Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol. 2020;75(20):25532566. doi:10.1016/j.jacc.2020.03.057

22. Tada H, Kawashiri MA, Nohara A, Inazu A, Mabuchi H, Yamagishi M. Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. Eur Heart J. 2017;38(20):15731579. doi:10.1093/eurheartj/ehx004

23. Virani SS, Alonso A, Benjamin EJ, et al. American heart association council on epidemiology and prevention statistics committee and stroke statistics subcommittee. Heart disease and stroke statistics-2020 update: a report from the American heart association. Circulation. 2020;141:e139e596.

24. Lozano P, Henrikson NB, Dunn J, et al. Lipid screening in childhood and adolescence for detection of familial hypercholesterolemia: evidence report and systematic review for the US preventive services task force. JAMA. 2016;316(6):645655. doi:10.1001/jama.2016.6176

25. Groselj U, Kovac J, Sustar U, et al. Universal screening for familial hypercholesterolemia in children: the Slovenian model and literature review. Atherosclerosis. 2018;277:383391. doi:10.1016/j.atherosclerosis.2018.06.858

26. Bell DA, Hooper AJ, Bender R, et al. Opportunistic screening for familial hypercholesterolaemia via a community laboratory. Ann Clin Biochem. 2012;49(6):534537. doi:10.1258/acb.2012.012002

27. Scicali R, Di Pino A, Platania R, et al. Detecting familial hypercholesterolemia by serum lipid profile screening in a hospital setting: clinical, genetic and atherosclerotic burden profile. Nutr Metab Cardiovasc Dis. 2018;28(1):3543. doi:10.1016/j.numecd.2017.07.003

28. Mirzaee S, Choy KW, Doery JCG, Zaman S, Cameron JD, Nasis A. The tertiary hospital laboratory; a novel avenue of opportunistic screening of familial hypercholesterolemia. Int J Cardiol Heart Vasc. 2019;23:100354. doi:10.1016/j.ijcha.2019.100354

29. Besseling J, Sjouke B, Kastelein JJ. Screening and treatment of familial hypercholesterolemia - lessons from the past and opportunities for the future (based on the anitschkow lecture 2014). Atherosclerosis. 2015;241(2):597606. doi:10.1016/j.atherosclerosis.2015.06.011

30. Tada H, Okada H, Nomura A, et al. Prognostic impact of cascade screening for familial hypercholesterolemia on cardiovascular events. J Clin Lipidol. 2021. doi:10.1016/j.jacl.2020.12.012

31. Rodenburg J, Vissers MN, Wiegman A, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation. 2007;116(6):664668. doi:10.1161/CIRCULATIONAHA.106.671016

32. Wu X, Pang J, Wang X, et al. Reverse cascade screening for familial hypercholesterolemia in high-risk Chinese families. Clin Cardiol. 2017;40(11):11691173. doi:10.1002/clc.22809

33. Vinson A, Guerra L, Hamilton L, Wilson DP. Reverse cascade screening for familial hypercholesterolemia. J Pediatr Nurs. 2019;44:5055. doi:10.1016/j.pedn.2018.09.011

34. Ibarretxe D, Rodrguez-Borjabad C, Feliu A, Bilbao J, Masana L, Plana N. Detecting familial hypercholesterolemia earlier in life by actively searching for affected children: the DECOPIN project. Atherosclerosis. 2018;278:210216. doi:10.1016/j.atherosclerosis.2018.09.039

35. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol. 2004;160(5):407420. doi:10.1093/aje/kwh236

36. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993;72(2):171176. doi:10.1016/0002-9149(93)90155-6

37. Harada-Shiba M, Ohta T, Ohtake A, et al. Joint Working Group by Japan Pediatric Society and Japan Atherosclerosis Society for Making Guidance of Pediatric Familial Hypercholesterolemia.Guidance for Pediatric Familial Hypercholesterolemia 2017.J Atheroscler Thromb. 2018 ;25(6):539553.

38. Eissa MA, Mihalopoulos NL, Holubkov R, Dai S, Labarthe DR. Changes in fasting lipids during puberty. J Pediatr. 2016;170:199205. doi:10.1016/j.jpeds.2015.11.018

39. Tada H, Nohara A, Kawashiri MA. Monogenic, polygenic, and oligogenic familial hypercholesterolemia. Curr Opin Lipidol. 2019;30(4):300306. doi:10.1097/MOL.0000000000000609

40. Masana L, Ibarretxe D, Rodrguez-Borjabad C, et al. Expert group from the Spanish arteriosclerosis society. Toward a new clinical classification of patients with familial hypercholesterolemia: one perspective from Spain. Atherosclerosis. 2019;287:8992. doi:10.1016/j.atherosclerosis.2019.06.905

41. France M. Homozygous familial hypercholesterolaemia: update on management. Paediatr Int Child Health. 2016;36(4):243247. doi:10.1080/20469047.2016.1246640

42. Raal FJ, Hovingh GK, Catapano AL. Familial hypercholesterolemia treatments: guidelines and new therapies. Atherosclerosis. 2018;277:483492. doi:10.1016/j.atherosclerosis.2018.06.859

43. Pottle A, Thompson G, Barbir M, et al. Lipoprotein apheresis efficacy, challenges and outcomes: a descriptive analysis from the UK lipoprotein apheresis registry, 19892017. Atherosclerosis. 2019;290:4451. doi:10.1016/j.atherosclerosis.2019.09.006

44. Kawagishi N, Satoh K, Akamatsu Y, et al. Long-term outcome after living donor liver transplantation for two cases of homozygous familial hypercholesterolemia from a heterozygous donor. J Atheroscler Thromb. 2007;14(2):9498. doi:10.5551/jat.14.94

45. Mlinaric M, Bratanic N, Dragos V, et al. Case report: liver transplantation in homozygous familial hypercholesterolemia (HoFH)-long-term follow-up of a patient and literature review. Front Pediatr. 2020;8:567895. doi:10.3389/fped.2020.567895

46. Santos RD, Stein EA, Hovingh GK, et al. Long-term evolocumab in patients with familial hypercholesterolemia. J Am Coll Cardiol. 2020;75(6):565574. doi:10.1016/j.jacc.2019.12.020

47. Malhotra A, Shafiq N, Arora A, Singh M, Kumar R, Malhotra S. Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemia. Cochrane Database Syst Rev. 1975;2014;2014(3):CD001918. doi:10.1152/ajplegacy.1975.229.3.570

48. Tada H, Nohara A, Inazu A, Sakuma N, Mabuchi H, Kawashiri M-A. Sitosterolemia, hypercholesterolemia, and coronary artery disease. J Atheroscler Thromb. 2018;25(9):783789. doi:10.5551/jat.RV17024

49. Tada H, Okada H, Nomura A, et al. Rare and deleterious mutations in ABCG5/ABCG8 genes contribute to mimicking and worsening of familial hypercholesterolemia phenotype. Circ J. 2019;83(9):19171924. doi:10.1253/circj.CJ-19-0317

50. Tada H, Kawashiri MA, Takata M, et al. Infantile cases of sitosterolaemia with novel mutations in the ABCG5 gene: extreme hypercholesterolaemia is exacerbated by breastfeeding. JIMD Rep. 2015;21:115122.

51. Tada H, Kawashiri MA, Okada H, et al. Assessments of carotid artery plaque burden in patients with familial hypercholesterolemia. Am J Cardiol. 2017;120(11):19551960. doi:10.1016/j.amjcard.2017.08.012

52. Tada H, Nakagawa T, Okada H, et al. Clinical impact of carotid plaque score rather than carotid intima-media thickness on recurrence of atherosclerotic cardiovascular disease events. J Atheroscler Thromb. 2020;27(1):3846. doi:10.5551/jat.49551

53. Okada H, Tada H, Hayashi K, et al. Aortic root calcification score as an independent factor for predicting major adverse cardiac events in familial hypercholesterolemia. J Atheroscler Thromb. 2018;25(7):634642. doi:10.5551/jat.42705

54. Tada H, Kawashiri MA, Okada H, et al. Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography. Am J Cardiol. 2015;115(6):724729. doi:10.1016/j.amjcard.2014.12.034

55. Tada H, Kawashiri MA, Nohara A, Inazu A, Mabuchi H, Yamagishi M. Assessment of arterial stiffness in patients with familial hypercholesterolemia. J Clin Lipidol. 2018;12(2):397402. doi:10.1016/j.jacl.2017.12.002

56. Dombalis S, Nash A. The effect of statins in children and adolescents with familial hypercholesterolemia: a systematic review. J Pediatr Health Care. 2020;S0891-5245(20)303084. doi:10.1016/j.pedhc.2020.11.007

57. Anagnostis P, Vaitsi K, Kleitsioti P, et al. Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials. Endocrine. 2020;69(2):249261. doi:10.1007/s12020-020-02302-8

58. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the national lipid association expert panel on familial hypercholesterolemia. J Clin Lipidol. 2011;5(3):133140. doi:10.1016/j.jacl.2011.03.001

59. Glueck CJ, Mellies MJ, Dine M, Perry T, Laskarzewski P. Safety and efficacy of long-term diet and diet plus bile acid-binding resin cholesterol-lowering therapy in 73 children heterozygous for familial hypercholesterolemia. Pediatrics. 1986;78(2):338348.

60. van der Graaf A, Cuffie-Jackson C, Vissers MN, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2008;52(17):14211429. doi:10.1016/j.jacc.2008.09.002

61. Santos RD, Ruzza A, Hovingh GK, HAUSER-RCT Investigators, et al.. Evolocumab in pediatric heterozygous familial hypercholesterolemia. N Engl J Med. 2020;383(14):13171327. doi:10.1056/NEJMoa2019910

62. Ramaswami U, Futema M, Bogsrud MP, Holven KB. Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis. 2020;292:178187. doi:10.1016/j.atherosclerosis.2019.11.012

63. Raal FJ, Rosenson RS, Reeskamp LF, ELIPSE HoFH Investigators, et al.. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711720. doi:10.1056/NEJMoa2004215

64. Tada H, Kawashiri MA, Nomura A, et al. Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease. J Clin Lipidol. 2018;12(6):14361444. doi:10.1016/j.jacl.2018.08.006

More:
[Full text] Familial Hypercholesterolemia: A Narrative Review on Diagnosis and Man | VHRM - Dove Medical Press

Read More...

Inspiring innovation | UDaily – UDaily

February 17th, 2021 1:54 am

Article by Karen B. Roberts Photo illustration by David Barczak February 15, 2021

According to Hungarian biochemist Albert Szent-Gyrgyi, who won the Nobel Prize in physiology or medicine in 1937 for his study of vitamin c and cell respiration, Innovation is seeing what everybody has seen and thinking what nobody has thought.

Most of the time, innovators do not know if their ideas will pan out. A lot of the time they dont. When failure occurs, inventors step back, reconsider and regroup, then keep pursuing their ideas, incorporating lessons learned along the way in order to pivot or start anew.

As we celebrate National Innovation Day on Tuesday, Feb. 16, UDaily asked several University of Delaware researchers who are fellows of the National Academy of Inventors to share their successes, stumbling blocks and suggestions on what it takes to innovate, invent and inspire new solutions to challenges facing society and the world.

Eleftherios (Terry) Papoutsakis is the Unidel Eugene Du Pont Chair ofChemical and Biomolecular Engineering. He was selected for NAI fellow status in December 2020 for translational biotechnology contributions that have profoundly impacted sustainable manufacturing and human health. One technology that Papoutsakis said has proven particularly useful and successful is his teams development of a method to engineer microparticles that deliver gene-regulating material to hematopoietic stem and progenitor cells that live deep in our bone marrow, where they direct the formation of blood cells. The technology could be useful in treatment for inherited blood disorders, such as sickle cell anemia, or to improve personalized medicine. The discovery, he said, was completely unexpected, but it is currently generating a lot of interest from companies.

Q: Were there inventors that you looked up to as a kid or other people or events that inspired your inventiveness?

Papoutsakis: As a child, I did not know what inventors do but I was amazed by the ability of airplanes to fly, thediscovery of plastics, fertilizers and pesticides (my dad hadan orchard and could tell how important they were) and theconcept of the vaccine. Mygeneration first experienced the benefits of the polio vaccine andvaccines for otherdevastatingdiseases. That iswhy I decided tobecome achemical engineer. I did not know at the time how broad thefield was, but I had a cousin-in-law who wasforward-looking, and he explained to me the potential of thefield and its breadth.

Q: What are some of the stumbling blocks youve encountered as an inventor? How did you overcome them?

Papoutsakis: Two things come to mind. First, I wish I had taken a course inpatent law and patent writing. I amstill learning as I go along; however, I cant help but think about what might have been different if Id had training. I missed several opportunities to protect my researchwork.

Second, Iwish I understood better how tosell (commercialize) myinventions and be good at it. It takes the right personality and athick skin to swallowwithoutpain therejections (and I lack both), plus a lot of time to keeppushing.

Q: Are the best innovators also subject-matter experts? Or do great innovations just as often or more often flow from an idea from someone who does not know how to bring that idea to life, but gets connected with someone who does?

Papoutsakis: Not necessarily, intuition and imagination are more important, I think. In terms of which is better, subject-matter expertise or connections, I think the latter is as potent anavenue as the subject-matter expertwho has intuition and imagination, orthe rightpeople towork with.

Q: What are the critical innovations we need now?

Papoutsakis: We havedone wellwith theeasy thingsthat make a lot of money like social media and the Googles and the Amazons of the world. We needthese things, and the folks that developed them aregeniuses. But we still need tosolvereallybig problems inenergy, the environment, global warming, sustainablemanufacturing and transportation. Then there is the problem of affordable and adaptable health care. The pandemic is just a reminder and anadvance notice asto whathumanity might beup against as wemoveforward.

Q: Are there ways to develop/nurture an innovative mind and keep that spark alive?

Papoutsakis: Patents are a key part of invention. I think it is important to engage both undergrads and graduate students in all aspects of the patent process early on. From patent applications to writing provisional patents and, later, work with lawyers to file the utility patents or even just to read them. It is so different from reading scientific papers. Having this knowledge and background early in ones academic or industrial career would be beneficial for an individual and for future inventors working with that individual to keep the spark alive.

Q: Is there anything you would tell your younger inventor self if you could?

Papoutsakis: At the risk of repeating myself, I would tell my younger self to take a course in patent writing and entrepreneurship, to work with a master in my field and tothink outside of the box. The best ideas are not necessarily based on expensive science.

Kristi Kiick, Blue and Gold Distinguished Professor of Materials Science and Engineering, was named a fellow of the National Academy of Inventors in 2019. Her research involves developing biomaterials to advance medicine, from healing wounds faster and improving chemotherapies, to treating heart and musculoskeletal diseases.Kiicks proudest moment of invention occurred as a graduate student at the California Institute of Technology when she discovered that the natural protein-synthesis machinery of E. coli can be tuned to use novel chemical groups not normally used by nature in protein synthesis. Specific enzymes that normally control what amino acids are included in proteins can simply be produced at higher levels in the bacterial cell. This change alone can permit an enormous range of chemically reactive proteins to be produced. Other scientists have built on Kiicks original approach to create applications that now help scientists learn about processes inside of cells in order to better understand development, disease and drug treatments.

Q: Were there inventors that you looked up to as a kid or other people or events that inspired your inventiveness?

Kiick: My exposure to and interest in invention occurred while I was a research scientist at Kimberly Clark Corporation. I was inspired by many of my co-workers, who each approached innovation and invention differently.Some people saw research articles and applied those findings to technical advances we were trying to make in our laboratories, and others found inspiration from the fundamental principles of the world around them.It was inspiring and a little bit intimidating for me to watch how these colleagues generated and implemented ideas.It definitely changed how I looked at science and its application in solving technical challenges.

Q: What are some of the stumbling blocks youve encountered as an inventor? How did you overcome them?

Kiick: Honestly, the biggest stumbling block for me was trusting my scientific intuition as a young scientist.It took me a long time to understand that my ideas could be novel and that what might appear as an experimental failure could actually be a new discovery.The thoughtful and supportive mentoring by my graduate adviser was pivotal in my making this transition.

Q: Are the best innovators also subject-matter experts? Or do great innovations just as often or more often flow from an idea from someone who does not know how to bring that idea to life, but gets connected with someone who does?

Kiick: The best innovations dont necessarily come from subject matter experts. Having a fresh look at a question or an idea can spark innovation. The implementation of many technical innovations is often best accomplished by a diverse team, where deep technical knowledge can be applied in a new way because someone has thought to look at the idea differently.

Q: What are the critical innovations we need now?

Kiick: I think there are still critical innovations to be made in how we apply massive amounts of data to create new technologies and social systems that allow us to be good stewards of our planet, our communities and ourselves.

Q: Are there ways to develop/nurture an innovative mind and keep that spark alive?

Kiick: As Walt Whitman said, Be curious, not judgmental.

Q: Is there anything you would tell your younger inventor self if you could?

Kiick: I just laughed out loud.I would say surround yourself with supportive people who are trying to make a positive difference. Say yes, and and not no, but. Travel more.Enjoy the journey.

Yushan Yan, Henry B. du Pont Chair in Chemical and Biomolecular Engineering, was named a fellow of the National Academy of Inventors in 2018. He is a co-inventor on more than 20 patents. Among his teams most recent inventions is a new class of ionically conducting polymers that have the potential to drastically reduce the cost of green hydrogen and fuel cells and to help deeply decarbonize all sectors of our economy. In 2019, Yan launched a startup called W7energy, now known as Versogen, alongside UD students and alumni to commercialize this new class of polymers and membranes. Hes proud to report that the company has grown rapidly over the last two years.

Q: Were there inventors that you looked up to as a kid or other people or events that inspired your inventiveness?

Yan: When I was a kid, I did not understand the concept of invention, per se, but I did like tinkering with my hands. For example, I enjoyed making my own primitive telescope or modifying my kerosene lamp to make it burn cleaner. Years later I would learn that what I did to the lamp was to turn the diffusion flame (where the fuel and oxidizer are separate prior to the reaction) into a premixed flame (where the fuel and oxidizer are mixed) like those found in a Bunsen burner.

Q: What are some of the stumbling blocks youve encountered as an inventor? How did you overcome them?

Yan: Coming up with an invention that is useful is not difficult, but developing a good sense of what kind of invention can be commercialized and have a measurable societal impact took some time.

Q: What are the critical innovations we need now?

Yan: As a society we still need many critical innovations in all kinds of fields. For myself, being able to reduce the cost of hydrogen and fuel cells to help deeply decarbonize our economy is a very high priority.

Q: Are there ways to develop/nurture an innovative mind and keep that spark alive?

Yan: I think it is important to instill curiosity into our children and to convince them that everyone has the potential to change what is possible.

See original here:
Inspiring innovation | UDaily - UDaily

Read More...

G-CON PODs Successfully Delivered for Cell Therapy Manufacturing on an Accelerated Timeline – PRNewswire

February 17th, 2021 1:54 am

"This project was a testament to the fact that rigorous planning and project execution lead to better results."

The advanced coordination between the facility and PODs reduced overlap and allowed for a predictable timeline and budget. Moreover, the client's having a single point of contact eliminated the risk of scope gaps that often lead to delay and increased project cost.

About G-CON Manufacturing

G-CON Manufacturing designs, builds and installs prefabricated G-CON POD cleanrooms. G-CON's POD portfolio provides cleanrooms in several dimensions for a variety of uses, from laboratory environments to personalized medicine and production process platforms. G-CON POD cleanroom units surpass traditional cleanroom structures in scalability, mobility and the possibility of repurposing the PODs once the production process reaches its lifecycle end. For more information, please visit G-CON's website athttp://www.gconbio.com.

About G-CON Building Services

G-CON Building Services simplifies pharmaceutical and biopharmaceutical cleanroom projects by providing effective turnkey host facility project management that leads to cost-efficient and on time results.

SOURCE G-CON Manufacturing

http://www.gconbio.com/

Read more here:
G-CON PODs Successfully Delivered for Cell Therapy Manufacturing on an Accelerated Timeline - PRNewswire

Read More...

Pharma Clinical Trial Digitization Market 2021 Rising Demand and Grow Opportunities Antidote Technologies, Aparito, Clinerion, CliniOps, Inc., KSU |…

February 17th, 2021 1:54 am

Clinical trial digitization allows the processing in different forms of voluminous patient-related data. Such data are being used by pharmaceutical companies to improve the effectiveness of trial execution.

Growing demand for quality data is expected to drive the market growth. Some of the other factors such as increasing demand for personalized drugs, increasing adoption of new technology in clinical research, growing research & development promoting outsourcing and increasing diseases prevalence will drive the market in the forecast period of 2020 to 2027

Competitive Landscape and Pharma Clinical Trial Digitization Market Share Analysis

Pharma clinical trial digitization market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to pharma clinical trial digitization market.

Pharma Clinical Trial Digitization Market Scope

The pharma clinical trial digitization market is segmented on the basis of countries into U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

All country based analysis of pharma clinical trial digitization market is further analyzed based on maximum granularity into further segmentation. On the basis of services, the pharma clinical trial digitization market is segmented into drug dose adjustment, drug impact monitoring, medical prescription system, bioprinting, preventive therapy, and individualized drug printing. Based on application, the market is segmented into clinical data management, trial monitoring, patient recruitment and enrollment. The pharma clinical trial digitization market on the basis of theme is segmented into digital continuity acrossclinical trial IT systems, patient-centric remote and virtual trial design and direct-to-patient home services.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-pharma-clinical-trial-digitization-market&pm

Key Pointers Covered in the Pharma Clinical Trial Digitization Market Industry Trends and Forecast to 2027

Pharma Clinical Trial Digitization Market Scenario

According to Data Bridge Market Research the market for pharma clinical trial digitization is increasing owing to the penetration of technology in the clinical research. The adoption of patient-centric remote and virtual trial design and direct-to-patient home services is helping the pharma clinical trial digitization to expand. Germination of health problems day by day is catering a good demand of research and technology, which on the whole is basic and keen parameter aiding to pharma clinical trial digitization market growth during the forecast period of 2020 to 2027.

Now the question is which are the other regions intuitive is targeting? Data Bridge Market Research has forecasted a large growth in theNorth America, owing to the advanced healthcare infrastructure. On the contrary Asia-Pacific (APAC) is expected to bounce the market growth exponentially due to surging players penetration and government initiatives taken.

Table of Contents-Snapshot Executive SummaryChapter 1 Industry OverviewChapter 2 Industry Competition by ManufacturersChapter 3 Industry Production Market Share by RegionsChapter 4 Industry Consumption by RegionsChapter 5 Industry Production, Revenue, Price Trend by TypeChapter 6 Industry Analysis by ApplicationsChapter 7 Company Profiles and Key Figures in Industry BusinessChapter 8 Industry Manufacturing Cost AnalysisChapter 9 Marketing Channel, Distributors and CustomersChapter 10 Market DynamicsChapter 11 Industry ForecastChapter 12 Research Findings and ConclusionChapter 13 Methodology and Data Source

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-pharma-clinical-trial-digitization-market&pm

Global Pharma Clinical Trial Digitization Market Scope and Market Size

Pharma clinical trial digitizationmarket is segmented of the basis of services, application and themes. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis of services, the pharma clinical trial digitization market is segmented into drug dose adjustment, drug impact monitoring, medical prescription system, bioprinting, preventive therapy, and individualized drug printing.Based on application, the market is segmented into clinical data management, trial monitoring, patient recruitment and enrollment.The pharma clinical trial digitization market on the basis of theme is segmented into digital continuity across clinical trial it systems, patient-centric remote and virtual trial design and direct-to-patient home services.

Pharma Clinical Trial Digitization Market Country Level Analysis

Pharma clinical trial digitization market is analysed and market size insights and trends are provided by services, application and themes as referenced above.

The countries covered in the pharma clinical trial digitization market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

The country section of the pharma clinical trial digitization market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

Pharma clinical trial digitization market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for pharma clinical trial digitization market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the pharma clinical trial digitization market. The data is available for historic period 2010 to 2018.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

See the article here:
Pharma Clinical Trial Digitization Market 2021 Rising Demand and Grow Opportunities Antidote Technologies, Aparito, Clinerion, CliniOps, Inc., KSU |...

Read More...

Worldwide Point of Care (PoC) Molecular Diagnostics Industry to 2030 – Impact Analysis of COVID-19 – ResearchAndMarkets.com – Business Wire

February 17th, 2021 1:54 am

DUBLIN--(BUSINESS WIRE)--The "Global Point of Care (PoC) Molecular Diagnostics Market 2020-2030 by Product (Assays, Instruments, Software), Technology (PCR, INAAT, Microarray), Application, End User, and Region: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

The global PoC molecular diagnostics market will reach $5,665.3 million by 2030, growing by 13.5% annually over 2020-2030 driven by increase in adoption of personalized medicine and surge in usage of PoC molecular diagnostics for drug discovery and development amid COVID-19 pandemic.

This report is based on a comprehensive research of the entire global PoC molecular diagnostics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.

In-depth qualitative analyses include identification and investigation of the following aspects:

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global PoC molecular diagnostics market in every aspect of the classification from perspectives of Product, Technology, Application, End User, and Region.

Key Players:

Key Topics Covered:

1 Introduction

1.1 Industry Definition and Research Scope

1.1.1 Industry Definition

1.1.2 Research Scope

1.2 Research Methodology

1.2.1 Overview of Market Research Methodology

1.2.2 Market Assumption

1.2.3 Secondary Data

1.2.4 Primary Data

1.2.5 Data Filtration and Model Design

1.2.6 Market Size/Share Estimation

1.2.7 Research Limitations

1.3 Executive Summary

2 Market Overview and Dynamics

2.1 Market Size and Forecast

2.1.1 Impact of COVID-19 on World Economy

2.1.2 Impact of COVID-19 on the Market

2.2 Major Growth Drivers

2.3 Market Restraints and Challenges

2.4 Emerging Opportunities and Market Trends

2.5 Porter's Five Forces Analysis

3 Segmentation of Global Market by Product

3.1 Market Overview by Product

3.2 Kits & Assays

3.3 Analyzers & Instruments

3.4 Software & Services

4 Segmentation of Global Market by Technology

4.1 Market Overview by Technology

4.2 Polymerase Chain Reaction (PCR)

4.2.1 Real-Time PCR (rt-PCR)

4.2.2 Digital PCR (d-PCR)

4.3 Isothermal Nucleic Acid Amplification Technology (INAAT)

4.4 Genetic Sequencing-based Technology

4.5 Microarray-based Technology

4.6 Other Technologies

5 Segmentation of Global Market by Application

5.1 Market Overview by Application

5.2 Infectious Disease

5.2.1 Respiratory Infections

5.2.2 Hospital Acquired Infections

5.2.3 Sexually Transmitted Infections

5.3 Gastrointestinal Infections

5.4 Oncology

5.5 Hepatitis

5.6 Prenatal/Neonatal Testing

5.7 Other Applications

6 Segmentation of Global Market by End User

6.1 Market Overview by End User

6.2 Hospitals

6.3 Clinics & Diagnostic Centers

6.4 Research and Academic Institutes

6.5 Other End Users

7 Segmentation of Global Market by Region

7.1 Geographic Market Overview 2019-2030

7.2 North America Market 2019-2030 by Country

7.2.1 Overview of North America Market

7.2.2 U.S.

7.2.3 Canada

7.2.4 Mexico

7.3 European Market 2019-2030 by Country

7.3.1 Overview of European Market

7.3.2 Germany

7.3.3 UK

7.3.4 France

7.3.5 Spain

7.3.6 Italy

7.3.7 Russia

7.3.8 Rest of European Market

7.4 Asia-Pacific Market 2019-2030 by Country

7.4.1 Overview of Asia-Pacific Market

7.4.2 Japan

7.4.3 China

7.4.4 Australia

7.4.5 India

7.4.6 South Korea

7.4.7 Rest of APAC Region

7.5 South America Market 2019-2030 by Country

7.5.1 Argentina

7.5.2 Brazil

7.5.3 Chile

7.5.4 Rest of South America Market

7.6 MEA Market 2019-2030 by Country

7.6.1 UAE

7.6.2 Saudi Arabia

7.6.3 South Africa

7.6.4 Other National Markets

8 Competitive Landscape

8.1 Overview of Key Vendors

8.2 New Product Launch, Partnership, Investment, and M&A

8.3 Company Profiles

9 Investing in Global Market: Risk Assessment and Management

9.1 Risk Evaluation of Global Market

9.2 Critical Success Factors (CSFs)

Originally posted here:
Worldwide Point of Care (PoC) Molecular Diagnostics Industry to 2030 - Impact Analysis of COVID-19 - ResearchAndMarkets.com - Business Wire

Read More...

Pharma Clinical Trial Digitization Industry 2021 With Covid-19 Impact on Market Research by Size, Top Leading Countries, Companies, Consumption,…

February 17th, 2021 1:54 am

A New Business Research Report released by DBMR with title Global Pharma Clinical Trial Digitization Market Study Forecast till 2027. This Report presents detailed competitive analysis including the market share, size, growth, trends, demand, revenue, cost structure, segment and future scope 2027. This study categorizes the global Health and Safety Products breakdown data by manufacturers, region, type and applications, also analyzes the market drivers, opportunities and challenges. This Global Pharma Clinical Trial Digitization market report brings data for the estimated year 2021 and forecasted till 2027 in terms of both, value (US$ MN) and volume (MT). The report also consists of forecast factors, macroeconomic factors, and a market outlook of the Pharma Clinical Trial Digitization market. The study is conducted by applying both top-down and bottom-up approaches and further iterative methods used to validate and size market estimation and trends of the Global Pharma Clinical Trial Digitization market. Pharma Clinical Trial Digitization Market Report will add the analysis of the impact of COVID-19 on this industry.

Get Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pharma-clinical-trial-digitization-market&aB

This upgradation of healthcare IT infrastructure and technological assistance being provided on vast scale is driving the market growth at the rate of 5.70% annual for the mentioned seven years. This momentum will be maintained by rising practice of individualized drug printing.

Data Bridge Market Research analyses the market to grow at a CAGR of 5.7% in the above-mentioned forecast period. Growing demand for personalized medicine is expected to create new opportunity for the pharma clinical trial digitization mark

Pharma Clinical Trial Digitization Market Overview:

Clinical trial digitization allows the processing in different forms of voluminous patient-related data. Such data are being used by pharmaceutical companies to improve the effectiveness of trial execution.

Growing demand for quality data is expected to drive the market growth. Some of the other factors such as increasing demand for personalized drugs, increasing adoption of new technology in clinical research, growing research & development promoting outsourcing and increasing diseases prevalence will drive the market in the forecast period of 2020 to 2027

Global Pharma Clinical Trial Digitization Market 2020 Reportencompasses an infinite knowledge and information on what the markets definition, classifications, applications, and engagements are and also explains the drivers and restraints of the market which is obtained from SWOT analysis. By applying market intelligence for this Pharma Clinical Trial Digitization Market report, industry expert measure strategic options, summarize successful action plans and support companies with critical bottom-line decisions. Additionally, the data, facts and figures collected to generate this market report are obtained forms the trustworthy sources such as websites, journals, mergers, newspapers and other authentic sources. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, price, cost, revenue and gross margins.

According to this report Global Pharma Clinical Trial Digitization Market will rise from Covid-19 crisis at moderate growth rate during 2020 to 2027. Pharma Clinical Trial Digitization Market includes comprehensive information derived from depth study on Pharma Clinical Trial Digitization Industry historical and forecast market data. Global Pharma Clinical Trial Digitization Market Size To Expand moderately as the new developments in Pharma Clinical Trial Digitization and Impact of COVID19 over the forecast period 2020 to 2027.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT, GET FREE COVID-19 SAMPLE @https://www.databridgemarketresearch.com/covid-19-impact/global-pharma-clinical-trial-digitization-market?ab

Pharma Clinical Trial Digitization Market report provides depth analysis of the market impact and new opportunities created by the COVID19/CORONA Virus pandemic. Report covers Pharma Clinical Trial Digitization Market report is helpful for strategists, marketers and senior management, And Key Players in Pharma Clinical Trial Digitization Industry.

Pharma Clinical Trial Digitization Market Segments Outlook:

By Services (Drug Dose Adjustment, Drug Impact Monitoring, Medical Prescription System, Bioprinting, Preventive Therapy, Individualized Drug Printing)

By Application (Clinical Data Management, Trial Monitoring, Patient Recruitment and Enrollment)

By Themes (Digital Continuity Across Clinical Trial IT Systems, Patient-centric Remote and Virtual Trial Design, Direct-to-patient Home Services)

List of Companies Profiled in the Pharma Clinical Trial Digitization Market Report are:

Antidote Technologies, Inc.AparitoClinerion Ltd.CliniOps, Inc.ConsilxDeep 6 AIKoneksa Health Inc.Medidata SolutionsOraclePatientsLikeMeTrialbeeTriNetX, Inc.Veeva SystemsComplete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart) @https://www.databridgemarketresearch.com/toc/?dbmr=global-pharma-clinical-trial-digitization-market&Ab

Pharma Clinical Trial Digitization Reportdisplays data on key players, majorcollaborations, merger & acquisitions along with trending innovation and business policies. The report highlights current and future market trends and carries out analysis of the effect of buyers, substitutes, new entrants, competitors, and suppliers on the market. The key topics that have been explained in this Pharma Clinical Trial Digitization market report include market definition, market segmentation, key developments, competitive analysis and research methodology. To accomplish maximum return on investment (ROI), its very essential to be acquainted with market parameters such as brand awareness, market landscape, possible future issues, industry trends and customer behavior where this Pharma Clinical Trial Digitization report comes into play.

Global Pharma Clinical Trial Digitization Market Scope and Market Size

On the basis of services, the pharma clinical trial digitization market is segmented into drug dose adjustment, drug impact monitoring, medical prescription system, bioprinting, preventive therapy, and individualized drug printing.

Based on application, the market is segmented into clinical data management, trial monitoring, patient recruitment and enrollment.

The pharma clinical trial digitization market on the basis of theme is segmented into digital continuity across clinical trial it systems, patient-centric remote and virtual trial design and direct-to-patient home services.

Market Size Segmentation by Region & Countries (Customizable):

North America (Canada, United States & Mexico)Europe (Germany, the United Kingdom, Benelux, France, Russia & Italy)Asia-Pacific (Japan, South Korea, China, India & Southeast Asia)South America (Argentina, Brazil, Peru, Colombia, Etc.)Middle East & Africa (United Arab Emirates, Egypt, Saudi Arabia, Nigeria & South Africa)Key Questions Answered

What impact does COVID-19 have made on Global Pharma Clinical Trial Digitization Market Growth & Sizing?

Who are the Leading key players and what are their Key Business plans in the Global Pharma Clinical Trial Digitization market?

What are the key concerns of the five forces analysis of the Global Pharma Clinical Trial Digitization market?

What are different prospects and threats faced by the dealers in the Global Pharma Clinical Trial Digitization market?

What are the strengths and weaknesses of the key vendors?

Major Key Contents Covered in Pharma Clinical Trial Digitization Market:

Introduction of Pharma Clinical Trial Digitization with development and status.

Manufacturing Technology of Pharma Clinical Trial Digitization with analysis and trends.

Analysis of Global Pharma Clinical Trial Digitization market Key Manufacturers with Company Profile, Product Information, Production Information, and Contact Information.

Analysis of Global Pharma Clinical Trial Digitization market Capacity, Production, Production Value, Cost and Profit

Analysis Pharma Clinical Trial Digitization Market with Comparison, Supply, Consumption, and Import and Export.

Pharma Clinical Trial Digitization market Analysis with Market Status and Market Competition by Companies and Countries.

2020-2027 Market Forecast of Global Pharma Clinical Trial Digitization Market with Cost, Profit, Market Shares, Supply, Demands, Import and Export

Trending factors influencing the market shares of APAC, Europe, North America, and ROW?

Pharma Clinical Trial Digitization Market Analysis of Industry Chain Structure, Upstream Raw Materials, Downstream Industry

Strategic Points Covered in Table of Content of Global Pharma Clinical Trial Digitization Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Pharma Clinical Trial Digitization market

Chapter 2: Exclusive Summary the basic information of the Pharma Clinical Trial Digitization Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Pharma Clinical Trial Digitization

Chapter 4: Presenting the Pharma Clinical Trial Digitization Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying market size by Type, End User and Region 2010-2019

Chapter 6: Evaluating the leading manufacturers of the Pharma Clinical Trial Digitization market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries (2020-2027).

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally, Pharma Clinical Trial Digitization Market is a valuable source of guidance for individuals and companies in decision framework.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:Corporatesales@databridgemarketresearch.com

View original post here:
Pharma Clinical Trial Digitization Industry 2021 With Covid-19 Impact on Market Research by Size, Top Leading Countries, Companies, Consumption,...

Read More...

A Guide to Disability Benefits and Psoriatic Arthritis – Healthline

February 17th, 2021 1:52 am

Psoriatic arthritis (PsA) is a condition that can be particularly debilitating and painful, causing intense flare-ups that cause joints to be become inflamed.

This can make mobility difficult sometimes impossible. Not surprisingly, that can affect the ability to work, no matter your profession.

Although people with PsA can have long periods of remission, with few symptoms or even none, the unpredictability of the condition could require extended periods away from a job, or hinder your ability to look for employment.

According to a 2016 study, one-third of people with PsA reported missing work because of their disease, and the condition impacted their ability to work full-time.

Disability insurance may be able to replace some of that income.

Social Security Disability Income (SSDI) is a federal disability insurance benefit for those who have paid into Social Security while working.

If youre in a low-income bracket and havent paid enough into Social Security during your working years to qualify for SSDI, youre not out of luck. In that case, you may be a candidate for a different program called supplemental security income (SSI).

For both SSDI and SSI, benefits are limited to people who fall under the definition of being unable to perform substantial, gainful activity, says Liz Supinski, director of data science at the Society for Human Resource Management.

There are limits on how much a person can earn and still collect, she adds about $1,200 for most people, or around $2,000 per month for blind people.

Some people are covered by private disability insurance, typically acquired through their work, Supinski says.

Having this type of insurance doesnt disqualify you from receiving SSDI, because its usually a short-term benefit with more limited amounts. Because of that, she notes that many people use this insurance to replace income as theyre navigating through the SSDI process.

The Social Security Administration (SSA) categorizes PsA under the classification of immune system impairments, and specifically under sections 14.00D6 and 14.09 as Inflammatory Arthritis.

This encompasses a spectrum of inflammatory arthritis conditions, but all with the main challenge of limiting your movements, mainly through joint pain, swelling, and tenderness.

In addition to PsA, this description could include other conditions like inflammatory bowel disease (IBD), ankylosing spondylitis, and reactive arthritis, also known as Reiters syndrome.

The SSA evaluates the severity of the condition in order to approve disability benefits and acknowledges that your PsA may involve other systems as well, such as:

Because your disability claim is likely to include these types of concerns as well as complications of joint inflammation, its essential to have your medical paperwork together, including insights from your primary care doctor and specialists.

You can apply for disability benefits while youre still employed if your symptoms are significantly impacting your work, although most people tend to apply once theyve left a position, possibly because of their condition, says Supinski.

Whether you have PsA, a different condition, or a combination of conditions, the process for establishing a disability claim will be much more streamlined if you have a breadth of information already in place, says Michelle Ogunwole, MD, a specialist in internal medicine and research fellow at The Johns Hopkins University School of Medicine.

If youre managing multiple health issues or a chronic condition like psoriatic arthritis, its already a good idea to compile your medical info in one place, so you have it available for appointments, she says.

That will also give you insight into trends you may not have been seeing before, like possible triggers for a flare-up, she adds.

If possible, have the following information on hand:

Also, let your doctors, colleagues, and family know youll be going through the application process. The SSA gathers input from healthcare providers as well as the applicant and sometimes asks for additional information from family members and co-workers to determine if you qualify as disabled based on SSA criteria.

Claiming disability benefits can be a complex and lengthy process, but taking the time to understand the criteria used by the SSA can help you get closer to getting a claim approved.

Consider reaching out to representatives at your local SSA field office, since they can help you apply for SSDI and SSI benefits.

Make an appointment by calling 800-772-1213, or you can also complete an application online at the SSA website.

Elizabeth Millard lives in Minnesota with her partner, Karla, and their menagerie of farm animals. Her work has appeared in a variety of publications, including SELF, Everyday Health, HealthCentral, Runners World, Prevention, Livestrong, Medscape, and many others. You can find her and way too many cat photos on her Instagram.

Read the rest here:
A Guide to Disability Benefits and Psoriatic Arthritis - Healthline

Read More...

Drug used to treat arthritis could save the lives of those sickest from COVID-19, study finds – ABC Action News

February 17th, 2021 1:52 am

TAMPA, Fla. A drug used for nearly a decade to prevent joint pain and swelling in those with arthritis could save your life from COVID-19. A new study is showing promising results with those sickest from the coronavirus.

Theres a promising drug doctors are using right now to treat the sickest of the sick. Its called Tocilizumab under the brand name Actembra.

This is basically another tool in the toolbox for us to help prevent people from getting severe COVID and die," said Dr. Michael Teng, a virologist at USF Health.

The antibody has been used to lessen the inflammation in patients with rheumatoid arthritis for nearly a decade now.

Preliminary findings of the RECOVERY Trial out of the U.K. show Tocilizumab also reduces the risk of death, shortens the amount of time someone is in the hospital and lessens the need for a ventilator.

If you get infected and have severe COVID now there's an additional drug that can help you survive," said Dr. Teng.

The same trial by the University of Oxford first discovered Dexamethasone was effective in fighting COVID.

So they've [researchers] tried things like anti-HIV drugs, which didn't work very well. They tried hydroxychloroquine and the study showed it didn't work very well," said Dr. Teng.

Dexamethasone was used on former President Donald Trump. Now it's part of standard care. Meanwhile, Tocilizumab would provide it a boost. The study shows for every 25 patients treated with the drug, one additional life would have been saved.

But is it necessary with millions of Americans now getting vaccinated? Doctor Teng insists it absolutely is necessary.

Only about 4% of our population has gotten both doses of vaccine. So that means there's a lot of people out there that are still susceptible to coronavirus infection.

Dr. Teng warns there are downsides to the drug.

It's expensive, it's not that widely available," he said.

Nonetheless, he believes, any tool to help in the fight against the pandemic is always welcome.

See original here:
Drug used to treat arthritis could save the lives of those sickest from COVID-19, study finds - ABC Action News

Read More...

How Does Abatacept Compare To Other bDMARDs in Rheumatoid Arthritis Treatment? – DocWire News

February 17th, 2021 1:52 am

A study evaluated the use of biologic disease-modifying antirheumatic drugs (bDMARDs) in the treatment of rheumatoid arthritis (RA), and compared outcomes between patients taking abatacept compared to other bDMARDs.

The retrospective study included patients with RA treated with abatacept as any line of therapy (LOT) at four different centers in the UK between January 2013 and December 2017.

Final analysis consisted of 213 patients who received up to eight LOTs. The mean age was 55.2 years, and most patients were female (71.4%). The median disease duration prior to initiating bDMARD therapy was 3.9 years (interquartile range, 2.1-8.5 years). Receipt of abatacept or any bDMARD was correlated with reduced six-month disease activity score for 28 joints (DAS28) erythrocyte sedimentation rate and DAS2 C-reactive protein (DAS28-CRP) scores. European League Against Rheumatism (EULAR) responses, measured as good, moderate, or no response, were better for patients when receiving abatacept compared to when receiving other bDMARDs, at six months (22.8% vs. 16.6%, 41.3% vs. 41.4%, and 35.9% vs. 42.1%, respectively) and one year (27.9% vs. 21.2%, 36.1% vs. 34.5%, and 36.1% vs. 44.2%, respectively).

The 68 patients who received abatacept as their first LOT were on treatment much longer compared to those receiving other bDMARDs (53.4 months vs. 17.4 months, P<0.01), and this was similar for the second LOT. Patients receiving other bDMARDs who stopped after six months were more likely to sustain an infection requiring antibiotics compared to patients receiving abatacept.

The study was published in BMC Rheumatology.

The researchers acknowledged the impact of the COVID-19 pandemic on treatment as well.

The rheumatology community is working to optimise disease management strategies and transition to telehealth. Early research suggests the risk of serious complications from COVID-19 is not increased for patients treated with bDMARDs or targeted synethic DMARDs. However, preventative withdrawal of these treatments, which may occur at the time of COVID-19 symptom onset, should be avoided due to the increased risk of relapse and morbidity. Future research should consider how abatacept and other bDMARDs are used in RA management during and after the pandemic, they recommended.

See the original post here:
How Does Abatacept Compare To Other bDMARDs in Rheumatoid Arthritis Treatment? - DocWire News

Read More...

Arthritis Knee Pain Centers Offers Therapy That Helps Reduce Osteoarthritis Knee Pain and Increase Mobility – Press Release – Digital Journal

February 17th, 2021 1:52 am

The medical practice group provides a non-surgical, non-opioid, outpatient pain relief program to patients around the country.

Osteoarthritis (OA) is the most common type of arthritis and affects more than 32 million adults in the United States alone. Known as the wear and tear arthritis, it occurs when the smooth cushion or the cartilage between bones breaks down, and causes joints to become painful, swollen and hard to move. The knee joint is the most common area for OA to strike and millions of people are hobbled by the debilitating pain, prohibiting them from carrying out everyday activities like climbing stairs, standing up from a seated position, or even standing for an extended amount of time.

Besides the challenge of managing the chronic pain, the consequential immobility and inactivity exacerbates other serious conditions such as obesity, diabetes, and heart disease. Arthritis Knee Pain Centers provides a comprehensive program that can help reduce pain and increase mobility without surgery or opioids.

Headquarted in Spring, Texas, Arthritis Knee Pain Centers growing network has practices all over the US. They specialize in a minimally invasive therapy designed to replenish depleted joint fluids with an FDA-approved cushioning gel. They use advanced digital imaging for precision placement, removing the guesswork that many of todays practitioners rely on to treat knee and joint pain.

Our singular clinical focus on treating osteoarthritis of the knee combined with our utilization of cutting-edge technology has allowed our specially trained physicians to excel at relieving the often debilitating chronic pain of our patients, says Dr. John J. Rush, Chief Medical Officer of Arthritis Knee Pain Centers. Weve successfully treated more than 20,000 patients since 2016.

Recognizing early warning signs of osteoarthritis can help slow down its progression. Some of its early warning signs are pain; stiffness and loss of flexibility; as well as a scraping or grating sensation when moving the knees. There are many ways that can help reduce the pain and the need for pain medication. Exercise and weight loss; physical therapy; and precision guided injections are some of the ways that can help manage osteoarthritis.

For more information on Arthritis Knee Pain Centers and osteoarthritis, visithttps://www.arthritiskneepain.com.

About Arthritis Knee Pain Centers

Arthritis Knee Pain Centers is a medical practice group that specializes in an FDA-approved pain relief therapy designed to help osteoarthritis sufferers decrease their knee joint pain. Headquartered in Spring, Texas, Arthritis Knee Pain Centers has practices in Texas, New York, Kentucky, Arizona, Ohio, North Carolina, South Carolina, and New Jersey.

Media ContactCompany Name: Arthritis Knee Pain CentersContact Person: Teresa JeffersonEmail: Send EmailPhone: 202-596-9229Country: United StatesWebsite: https://www.arthritiskneepain.com/

Read the rest here:
Arthritis Knee Pain Centers Offers Therapy That Helps Reduce Osteoarthritis Knee Pain and Increase Mobility - Press Release - Digital Journal

Read More...

Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab,…

February 17th, 2021 1:52 am

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Healthcare today announced that on February 11th, the European Commission (EC) has granted marketing authorisation for Yuflyma (CT-P17), an adalimumab biosimilar, across all thirteen intended indications for the treatment of multiple chronic inflammatory diseases.

The EC approval of Yuflyma follows the recommendation for marketing authorisation issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in December 2020. The marketing authorisation is based on analytical, preclinical and clinical studies, demonstrating that Yuflyma is comparable to adalimumab, the reference product, in terms of safety, efficacy, PK/PD and immunogenicity up to 24 weeks1 and 1 year2 following treatment. Based on the results of the pivotal study, a high concentration formulation of Yuflyma has been approved for use in the European Union (EU), in patients with thirteen chronic inflammatory diseases; rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), axial spondyloarthritis without radiographic evidence of AS (nr-axSpA), psoriatic arthritis (PsA), psoriasis (PsO), paediatric plaque psoriasis (pPsO), hidradenitis suppurativa (HS), Crohns disease (CD), paediatric Crohns disease (pCD), ulcerative colitis (UC), uveitis (UV) and paediatric uveitis (pUV).

In Europe, according to IQVIA data, 60% of the whole adalimumab market has been taken by high concentration formulation and over 90% of the original adalimumab market has already been replaced with a high concentration version. With high concentration, low-volume, and consequently less pain, adalimumab can improve treatment adherence at the very least. Therefore, we focused on development of a high concentration biosimilar to provide a significant alternative to the adalimumab treatment category, said Dr. HoUng Kim, Ph.D., Head of Medical and Marketing Division at Celltrion Healthcare. In terms of the administration device, we have looked to ensure improved convenience for patients as well as providers with the inclusion of needle size (29G), latex-free to reduce allergy risk, and a long storage period or shelf life at room temperature for 30 days.

Professor Rieke Alten, Head of the Department of Internal Medicine, Rheumatology, Clinical Immunology and Osteology at Schlosspark-Klinik, Teaching Hospital of Charit, Berlin, Germany said, Over the past two decades, anti-tumour necrosis factor (TNF) biologics have revolutionised the management of chronic immune-mediated inflammatory diseases, but some of the features needed improvement for patients to reach their therapeutic goals. As a physician, we welcome these value-added features such as high concentration and low-volume formulations to reduce injection discomfort.

The centralised marketing authorisation granted by the EC is valid in all EU Member States as well as in the European Economic Area countries Iceland, Liechtenstein and Norway. This announcement will enable affordable access to a high concentration adalimumab biosimilar, broadening treatment alternatives for patients suffering with chronic inflammatory disease including rheumatoid arthritis, psoriasis, Crohns disease and ulcerative colitis.

Celltrion will take the EC Decision Reliance Procedure (ECDRP) to minimise lead time to launch the product in the UK and remains committed to delivering innovative and affordable medications to promote patients access to advanced therapies.

- ENDS -

Notes to Editors:

About CT-P17 (biosimilar adalimumab)

CT-P17 is the first proposed high concentration, low- volume and citrate-free adalimumab biosimilar. CT-P17 is indicated for the treatment of patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), axial spondyloarthritis without radiographic evidence of AS (nr-axSpA), psoriatic arthritis (PsA), psoriasis (Ps), paediatric plaque psoriasis (pPs), hidradenitis suppurativa (HS), Crohns disease (CD), paediatric Crohns disease (pCD), ulcerative colitis (UC), uveitis (UV) and paediatric uveitis (pUV). CT-P17 is a recombinant human monoclonal antibody that contains the active ingredient adalimumab. Adalimumab is a fully human antitumour necrosis factor (anti-TNF) monoclonal antibody. CT-P17 provides pain-reducing features as it comes with citrate-free formulation, meaning it causes less pain upon injection.

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us

References

1 J. Kay., et al. (2020). A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis. Poster Presented at ACR Convergence 20202 Data on file

Read more here:
Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab,...

Read More...

Scottish university teams up with US pharmaceuticals giant for research on immunological diseases, including arthritis – HeraldScotland

February 17th, 2021 1:52 am

THE University of Glasgow is embarking on a 4.6 million, four-year research collaboration with US-based pharmaceuticals group Eli Lilly and Company to discover and validate the next generation of drug targets for immunological diseases.

Led by the universitys Institute of Infection, Immunity and Inflammation, the collaboration will work across four diseases: psoriatic arthritis, rheumatoid arthritis, fibrosis, and vasculitis.

The university said it was hoped the collaboration between its scientists and those of Lilly would help enable the identification of first-in-class therapeutics for people suffering with these devastating and costly conditions.

READ MORE:Ian McConnell: Brexit could have taken many forms. Cheshire Cat Boris Johnson chose this one

It added: Rheumatoid arthritis alone affects 0.3 per cent to 1% of people across the globe and it is estimated that, within ten years of diagnosis, 40% of people will be unable to stay in full-time work. This has major socio-economic repercussions. In the UK, this costs the NHS on average 700 million per year and indirectly costs the UK economy an estimated 8 billion per year.

University of Glasgow principal Professor Sir Anton Muscatelli said: Glasgows researchers have a vision to drive forward innovation, in order to tackle some of societys most urgent challenges. The Glasgow-Lilly collaboration is well positioned to be an inspiring example of this vision and of the exciting possibilities of industry and academia working together. I look forward to seeing this important partnership progress, advancing the next generation of first-in-class therapeutic agents and their alignment with precision medicine approaches.

READ MORE:Brexit: Ian McConnell: The inconvenient truths for think big Boris Johnson, flagged by Emmanuel Macron and Danny Blanchflower

The University of Glasgow team is led by Carl Goodyear, and includes Stefan Siebert, Mariola Kurowska-Stolarska, Neal Millar, Neil Basu and Thomas Otto.

Ajay Nirula, vice-president of immunology at Lilly, said: Lillys research efforts continue to expand beyond our own laboratories to include unique partnerships with top academic institutions such as the University of Glasgow. We look forward to collaborating closely with the scientific team at UofG to discover potential new therapies for immunological disorders.

Link:
Scottish university teams up with US pharmaceuticals giant for research on immunological diseases, including arthritis - HeraldScotland

Read More...

Google News’ "Genetics" Section Is Full of Articles About People Named Gene – Futurism

February 14th, 2021 7:30 pm

Why is Google pulling up "Genetics" stories about Gene Simmons?Celebrity Gossip

If you try to look up the latest genetics news on Google News right now, youll find less information on the latest biomedical research and perhaps a little bit more about celebrities than you expected.

Google News algorithm seems to be pulling stories about people named Gene into the mix the news feed is full of articles about KISS frontman Gene Simmons, comedian Amy Schumers son Gene, and former National Economic Council Director Gene Sperling. Its a harmless glitch, to be sure, but also a bit puzzling given Googles global leadership in the AI industry.

A Google spokesperson told Futurism that theyre going to look into this, but didnt clarify what went wrong with the Google News algorithm or why.

But from an outsiders perspective, it seems like someone at Google told the algorithm to feature stories that have the word gene in their headline without checking whether they talk about music icons or cellular biology. To be fair, it gets confusing.

Well let you know if Google gets back to us, but the more likely outcome is that the glitch gets quietly fixed without Google announcing that something went wrong. Still, were holding out hope that well learn about some intern who accidentally cranked a big lever with Gene news written on it all the way up or something like that.

In the meantime, feel free to enjoy the feed of carefully-curated biomedical and KISS news that Google put together.

More on questionable science news: This Awful Tabloid Predicts a Killer Asteroid Almost Every Day

More here:
Google News' "Genetics" Section Is Full of Articles About People Named Gene - Futurism

Read More...

Global Animal Genetics Market Forecast to 2027 by Product (Poultry, Porcine, Bovine, Canine), Material (Semen and Embryo), and Services (DNA Typing,…

February 14th, 2021 7:30 pm

DUBLIN--(BUSINESS WIRE)--The "Animal Genetics Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Product (Poultry, Porcine, Bovine, Canine, and Others), Genetic Material (Semen and Embryo), and Services (DNA Typing, Genetic Trait Tests, Genetic Disease Tests, and Others) and Geography." report has been added to ResearchAndMarkets.com's offering.

Genetic material and Services the market is expected to reach US$ 7,705.23 million by 2027 from US$ 4,778.67 million in 2019. The market is estimated to grow at a CAGR of 6.3% from 2020 to 2027.

Based on product, the market is segmented into poultry, porcine, bovine, canine, and others. In 2019, the porcine segment accounted for the highest share of the market. Growth of this segment is attributed to rise in production of porcine and increase in pork consumption across the globe. The same segment is likely to register highest CAGR in the global animal genetics market during the forecast period.

In terms of genetic material, the animal genetics market is segmented into embryo and semen. The embryo segment held the largest share of the market in 2019, whereas the semen segment is anticipated to register the highest CAGR of 7.0% in the market during the forecast period.

COVID-19 pandemic has become the most significant challenge across the world. This challenge would be frightening, especially in developing countries across the globe, as it may lead to reducing imports due to disruptions in global trade, which further increases the shortages of meat and dairy product supplies, resulting in a considerable price increase. Asian countries such as China, South Korea, and India are severely affected due to COVID-19 outbreak.

NEOGEN Corporation, HENDRIX GENETICS BV, Zoetis Inc., Genus, TOPIGS NORSVIN, Envigo, VetGen, ANIMAL GENETICS INC., ALTA GENETICS INC., and Groupe Grimaud are among the leading companies operating in the animal genetics market.

Key Topics Covered:

1. Introduction

1.1 Scope of the Study

1.2 Report Guidance

1.3 Market Segmentation

2. Animal Genetics Market - Key Takeaways

3. Research Methodology

4. Animal Genetics Market - Market Landscape

4.1 Overview

4.2 PEST Analysis

4.3 Expert Opinions

5. Animal Genetics Market - Key Market Dynamics

5.1 Market Drivers

5.1.1 Growing Preference for Animal Derived Proteins Supplements and Food Products.

5.1.2 Rising Adoption of Progressive Genetic Practices Such as Artificial Insemination (AI) and Embryo Transfer

5.2 Market Restraints

5.2.1 Limited Number of Skilled Professionals in Veterinary Research

5.2.2 Stringent Government Regulations for Animal Genetics

5.3 Market Opportunities

5.3.1 Innovations in Phenotyping Services

5.4 Future Trends

5.4.1 Significant Investments in R&D and Expansions Undertaken by Market Players

5.5 Impact Analysis

6. Animal Genetics Market - Global Analysis

6.1 Global Animal Genetics Marker Revenue Forecast and Analysis

6.2 Global Animal Genetics Market, By Geography - Forecast And Analysis

6.3 Market Positioning of Key Players

7. Animal Genetics Market Analysis - By Product

7.1 Overview

7.2 Animal Genetics Market Revenue Share, by Product (2019 and 2027)

7.3 Poultry

7.4 Porcine

7.5 Bovine

7.6 Canine

8. Animal Genetics Market Analysis - By Genetic Material

8.1 Overview

8.2 Animal Genetics Market Revenue Share, by Genetic Material(2019 and 2027)

8.3 Semen

8.4 Embryo

9. Animal Genetics Market Analysis - By Service

9.1 Overview

9.2 Animal Genetics Market Share, by Service, 2019 and 2027, (%)

9.3 DNA Typing

9.4 Genetic Trait Tests

9.5 Genetic Disease Tests

10. Animal Genetics Market Analysis and Forecasts To 2027 - Geographical Analysis

11. Impact of COVID-19 Pandemic On Global Animal Genetics Market

11.1 North America: Impact Assessment of COVID-19 Pandemic

11.2 Europe: Impact Assessment of COVID-19 Pandemic

11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic

11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Industry Landscape

12.1 Overview

12.2 Growth Strategies Done by the Companies in the Market, (%)

12.3 Organic Developments

12.3.1 Overview

12.4 Inorganic Developments

12.4.1 Overview

13. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/6ynx7z

View post:
Global Animal Genetics Market Forecast to 2027 by Product (Poultry, Porcine, Bovine, Canine), Material (Semen and Embryo), and Services (DNA Typing,...

Read More...

Genetics the next frontier of healthcare – Bangkok Post – Bangkok Post

February 14th, 2021 7:30 pm

China is banking on genetics as the next frontier of modern healthcare. From genetic testing and sequencing to gene therapy and precision medicine, this range of transformative technologies and services can underpin medical treatments and inform lifestyle choices.

Precision medicine -- using genetic information to determine treatments -- enables healthcare to move away from a one-size-fits-all approach where patients are treated with the same therapy, to one where targeted treatments are based on a patient's DNA and biomarkers.

The Chinese government and private sector are leading the charge globally, encouraging nationwide collection of DNA samples and investing in data analysis tools.

The Beijing Genome Institute, the world's largest sequencer and repository of genetic material, says it is capable of decoding the entire genomes of 100,000 people a year for no more than US$100 per person. In 2017, genetic testing was listed in China's 13th Five-Year Plan as one of the key growth strategies for the life sciences sector.

While some companies continue to work on breakthrough technology for whole-genome sequencing, others are focusing on the direct-to-consumer DNA test industry that only analyses small sections of a person's DNA. These consumer tests are marketed at younger people who are interested in their genealogy or are seeking health predictions and suggestions for lifestyle adjustments.

For as little as $3, you can provide a saliva sample to a company in exchange for information such as risks of developing chronic illnesses, how to lose weight and how to care for your skin. This market is expected to generate sales of $405 million in China by next year.

Last December, the consumer genetic testing company Genebox raised $14 million in financing. It has lowered the price a DNA test to 19.90 yuan ($3) since entering the market in 2018. More than 2.2 million people in China had used Genebox's service as of the end of 2019. This number is forecast to increase to 56.8 million by 2022, according to the consultancy Yi Ou.

As mass-market genetic testing becomes more commonplace, and the Chinese government ramps up efforts to develop its national DNA database, observers have raised the issue of privacy and personal data protection.

Companies such as Genebox have committed to not sharing personal information with third parties. However, exceptions exist, including having to comply with laws and regulations, as well as sharing user data with subsidiaries and related organisations for medical research and product development purposes.

Currently, China does not have specific legislation in place to protect personal data, including genetic data, at the national level. However, regulations are being developed. The Standing Committee of the National People's Congress of China has outlined a legislative agenda for a data protection law that is set to be enacted next year.

Overcoming data privacy concerns will be key to unleashing the full benefits of genetic testing. Structural efforts should be made to overcome these issues, such as transparency over how such powerful personal data is used. Close collaboration is needed between genetic testing companies, doctors, patient rights advocates, regulatory agencies and insurers.

Although precision medicine is still in its infancy, it is attracting great interest, including from Thailand. I hope the new privacy laws due to be introduced this year are broad enough to cover these emerging technologies so that we are ready to protect people once they become mainstream.

Link:
Genetics the next frontier of healthcare - Bangkok Post - Bangkok Post

Read More...

Front Range Biosciences Introduces A New Class of THCv Genetics That Will Boost Market Opportunities for New Consumer Experiences and Functional…

February 14th, 2021 7:30 pm

BOULDER, Colo., Feb. 9, 2021 /PRNewswire/ -- Front Range Biosciences ("FRB"), a cannabis and hemp genetics platform company, leveraging next generation breeding technology and R&D, todaybecame one of the first genetics providers to launch a new product line of high THCv plant varieties, in California, with availability in Colorado through licensed partners leveraging FRB's technology platform. This first generation product line is among the highest producers of THCv available, containing more than 20% total cannabinoids, more than 8% THCv, and over 2% grassy and fruity terpenes. These new varieties yield twice the yield of typical THCv producing plants. THCv is rare and has been an elusive minor cannabinoid until now, with exciting new properties for consumers that report appetite suppression and energizing, less psychoactive experiences.

"FRB is continually developing new genetics to help growers, brands, and consumers find new applications for cannabis," said Dr. Jonathan Vaught, CEO of Front Range Biosciences. "The cannabis market is evolving quickly, and consumers are constantly looking for new and unique experiences, just like in other CPG industries. We are leveraging genomics driven breeding to rapidly develop new products for cannabis companies and brands, unlocking new product opportunities from the incredible diversity of chemistry this plant produces. THCv represents just one of many new products we are making more accessible to the supply chain from this versatile plant through breeding, and we have many other unique products in development for other potential categories like edible ingredients, nutraceuticals and even pharmaceuticals.

This is the first THCv product line from FRB's world-renowned breeding program and expansive cannabis genetics library. This revolutionary THCv variety will pave the way for more unique consumer products, medical research and therapeutics. There is also a growing body of research linking THCv to a number of potential therapeutic benefits, including regulating tremors and seizures in ALS and Parkinson's patients, blocking fight or flight responses in PTSD, and acting as an effective analgesic for treating pain and migraines.

Since FRB's strain debuted on the market in California, it has become a favorite among local consumers. "It has a smooth, spicy-sweet smoke that creates a functional high. The THCv allows me to stay focused throughout the day, and I love that it's the opposite of most cannabis flower and keeps the munchies at bay," said Tricia Goldberg.

FRB's latest offering makes THCv more accessible by providing genetics that drastically increase yields, significantly reduce harvest times, deliver a variety of terpenes for improved flavor, as well as produce significantly higher levels of THCv, compared to the limited number of other THCv genetics that are currently available. These improvements in the finished product profile will open the door for new product opportunities for THCv flower-based products including smokable flower, pre-rolls, and concentrates, providing exciting new experiences for cannabis consumers.

"THCv, along with other minor cannabinoids, terpenes, and even flavonoids, have been a challenging group of traits for breeders to develop while maintaining the level of vigor and yield needed to introduce these products into the supply chain effectively," says Dr. Reggie Gaudino, VP of R&D for Front Range Biosciences. "The many years of genomics and chemistry research our team has been committed to for cannabis is allowing us to help growers and product companies do so much more with the plant than what was possible, even just a few years ago."

Growers have faced challenges producing cannabis containing high THCv content. The price of THCv has remained high due to significant lack of supply, and product availability has been extremely limited. This new class of THCv genetic products provides a timely solution to both issues, creating lucrative opportunities for cultivators and operators.

About Front Range Biosciences

Front Range Biosciences is a premier cannabis and hemp genetics platform company, creating and supporting innovative new products across multiple industries by combining next generation agricultural technologies with the world's top hemp and cannabis R&D program. FRB provides leading-edge solutions to growers, brands, and product manufacturers through its unique varieties of seeds, young plants, and technology licensing to drive product development and production efficiency for cannabis and hemp derived products. Since 2015, the company has been dedicated to creating new product opportunities and solving challenges throughout the supply chain by leveraging proprietary next generation breeding, chemistry, and tissue culture technologies. In addition to FRB's groundbreaking technology, the company has also established genetics services dedicated to the California market and a Shimadzu sponsored Hemp Center of Excellence with top-tier researchers to encourage further innovation in the industry. FRB is the company of choice for cultivators that demand unique, quality, consistent products. For more information on Front Range Biosciences, visit http://www.frontrangebio.com.

Media Contact

MATTIO Communications

frb@mattio.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/front-range-biosciences-introduces-a-new-class-of-thcv-genetics-that-will-boost-market-opportunities-for-new-consumer-experiences-and-functional-products-301224797.html

SOURCE Front Range Biosciences

Original post:
Front Range Biosciences Introduces A New Class of THCv Genetics That Will Boost Market Opportunities for New Consumer Experiences and Functional...

Read More...

Page 207«..1020..206207208209..220230..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick